

### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	57	55.8	102.2	(77.4-132.4)	Male	12	28.8	41.7	(21.5-72.9)
Female	33	23.1	142.6	(98.1-200.2)	Female	27	25.4	106.3	(70.1-154.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	10	11.0	91.1	(43.6-167.6)	Male	9	7.7	116.5	(53.2-221.2)
Female	8	10.0	79.8	(34.3-157.2)	Female	6	7.2	83.4	(30.4-181.5)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.7	nc	(nc-nc)	Male	29	28.4	102.0	(68.3-146.4)
Female	215	230.0	93.5	(81.4-106.8)	Female	30	28.7	104.5	(70.5-149.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	19	11.1	171.3	(103.1-267.5)	Male	19	20.8	91.5	(55.1-142.9)
Female					Female	10	11.4	87.6	(41.9-161.1)
Colon / Rectum					Ovary				
Male	105	85.9	122.2	(99.9-147.9)					
Female	105	95.3	110.1	(90.1-133.3)	Female	21	23.9	88.0	(54.5-134.6)
Esophagus					Pancreas				
Male	15	13.3	112.5	(62.9-185.6)	Male	17	15.9	106.9	(62.3-171.2)
Female	5	4.7	107.5	(34.6-250.8)	Female	15	19.8	75.6	(42.3-124.7)
Hodgkin Lymphoma					Prostate				
Male	4	5.3	nc	(nc-nc)	Male	195	224.5	86.9	(75.1-100.0)
Female	3	4.7	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	24	21.9	109.7	(70.2-163.2)	Male	15	14.7	102.3	(57.2-168.8)
Female	22	16.1	136.8	(85.7-207.2)	Female	25	10.3	243.8	(157.7-359.9)
Larynx					Testis				

Male	8	9.8	81.3	(35.0-160.2)	Male	2	10.1	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)					
Leukemia					Thyroid				
Male	12	17.3	69.2	(35.7-121.0)	Male	5	5.8	86.7	(27.9-202.4)
Female	23	16.0	143.6	(91.0-215.5)	Female	25	19.5	128.4	(83.1-189.6)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	12	10.1	118.4	(61.1-206.8)					
Female	7	4.5	155.8	(62.4-321.0)	Female	35	45.0	77.8	(54.2-108.2)
Lung and Bronchus					All Sites / Types				
Male	132	108.4	121.7	(101.8-144.3)	Male	722	746.7	96.7	(89.8-104.0)
Female	104	104.5	99.5	(81.3-120.6)	Female	801	771.8	103.8	(96.7-111.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

176  
Manchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	7.0	71.8	(23.1-167.6)	Male	5	3.5	144.9	(46.7-338.1)
Female	6	2.5	237.9	(86.9-517.8)	Female	2	2.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	38	27.0	140.6	(99.5-193.0)	Female	2	3.1	nc	(nc-nc)

Cervix Uteri					Oral Cavity & Pharynx						
	Male	2	1.2	nc	(nc-nc)		Male	2	2.7	nc	(nc-nc)
	Female	2	1.2	nc	(nc-nc)		Female	4	1.3	nc	(nc-nc)
Colon / Rectum					Ovary						
	Male	7	10.8	65.0	(26.0-133.9)						
	Female	4	10.1	nc	(nc-nc)		Female	3	2.7	nc	(nc-nc)
Esophagus					Pancreas						
	Male	1	1.7	nc	(nc-nc)		Male	2	2.0	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)		Female	3	2.1	nc	(nc-nc)
Hodgkin Lymphoma					Prostate						
	Male	0	0.5	nc	(nc-nc)		Male	31	29.8	104.1	(70.7-147.8)
	Female	0	0.4	nc	(nc-nc)						
Kidney & Renal Pelvis					Stomach						
	Male	0	2.8	nc	(nc-nc)		Male	1	1.8	nc	(nc-nc)
	Female	1	1.8	nc	(nc-nc)		Female	2	1.1	nc	(nc-nc)
Larynx					Testis						
	Male	1	1.3	nc	(nc-nc)		Male	0	0.7	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)						
Leukemia					Thyroid						
	Male	3	2.0	nc	(nc-nc)		Male	0	0.6	nc	(nc-nc)
	Female	1	1.7	nc	(nc-nc)		Female	2	1.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS						
	Male	1	1.3	nc	(nc-nc)						
	Female	0	0.5	nc	(nc-nc)		Female	2	5.5	nc	(nc-nc)
Lung and Bronchus					All Sites / Types						
	Male	9	13.9	64.9	(29.6-123.1)		Male	76	94.1	80.8	(63.6-101.1)
	Female	9	11.8	76.1	(34.7-144.5)		Female	90	86.2	104.4	(83.9-128.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

177 Mansfield									
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	14	13.3	105.5	(57.6-177.0)	Male	16	8.6	187.1	(106.9-303.8)
Female	4	4.7	nc	(nc-nc)	Female	11	7.5	146.5	(73.0-262.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	3.7	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.5	nc	(nc-nc)	Male	7	8.1	86.0	(34.4-177.1)
Female	68	62.9	108.0	(83.9-137.0)	Female	2	6.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	5	3.7	133.6	(43.1-311.8)	Male	8	6.4	126.0	(54.2-248.2)
					Female	4	2.8	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	27	21.2	127.4	(84.0-185.4)					
Female	21	18.8	111.8	(69.2-170.9)	Female	10	6.3	159.8	(76.5-293.9)
Esophagus					Pancreas				
Male	9	3.5	256.7	(117.2-487.4)	Male	1	4.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	1.8	nc	(nc-nc)	Male	43	56.1	76.7	(55.5-103.3)
Female	4	1.5	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	5	6.3	79.2	(25.5-184.8)	Testis	Male	4	3.7	nc	(nc-nc)
	Female	3	3.8	nc	(nc-nc)		Female	3	2.0	nc	(nc-nc)
Leukemia	Male	1	2.7	nc	(nc-nc)	Thyroid	Male	7	3.7	187.0	(74.9-385.4)
	Female	0	0.7	nc	(nc-nc)		Female	8	7.0	114.4	(49.3-225.5)
Liver and Intrahepatic Bile Ducts	Male	4	5.1	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Male	2	2.0	nc	(nc-nc)
	Female	3	4.1	nc	(nc-nc)		Female	12	11.6	103.5	(53.4-180.7)
Lung and Bronchus	Male	1	2.9	nc	(nc-nc)	All Sites / Types	Male	194	195.2	99.4	(85.9-114.4)
	Female	1	0.9	nc	(nc-nc)		Female	204	189.1	107.9	(93.6-123.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

178  
Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	29	26.1	111.2	(74.5-159.7)	Male	37	13.0	284.8	(200.5-392.6)
Female	13	9.3	139.5	(74.2-238.6)	Female	17	10.3	165.6	(96.4-265.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	8	4.8	168.0	(72.3-331.0)	Male	0	3.7	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
Male	1	0.8	nc	(nc-nc)		Male	15	12.8	117.3	(65.6-193.5)
Female	132	100.9	130.8	(109.4-155.1)		Female	10	11.6	86.6	(41.4-159.2)
Cervix Uteri						Oral Cavity & Pharynx				
Female	2	4.5	nc	(nc-nc)		Male	6	10.0	59.8	(21.8-130.1)
						Female	5	4.8	104.6	(33.7-244.2)
Colon / Rectum						Ovary				
Male	39	40.3	96.9	(68.9-132.4)						
Female	42	37.8	111.1	(80.0-150.1)		Female	11	10.2	108.1	(53.9-193.4)
Esophagus						Pancreas				
Male	4	6.4	nc	(nc-nc)		Male	10	7.5	133.0	(63.7-244.7)
Female	1	1.9	nc	(nc-nc)		Female	10	7.8	127.6	(61.1-234.8)
Hodgkin Lymphoma						Prostate				
Male	0	1.8	nc	(nc-nc)		Male	125	108.0	115.8	(96.4-137.9)
Female	0	1.6	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	8	10.4	76.9	(33.1-151.5)		Male	5	6.8	73.0	(23.5-170.4)
Female	4	6.7	nc	(nc-nc)		Female	3	4.0	nc	(nc-nc)
Larynx						Testis				
Male	3	4.8	nc	(nc-nc)		Male	7	2.8	245.8	(98.5-506.5)
Female	0	1.2	nc	(nc-nc)						
Leukemia						Thyroid				
Male	7	7.8	90.2	(36.1-185.8)		Male	2	2.3	nc	(nc-nc)
Female	5	6.4	78.6	(25.3-183.4)		Female	8	7.6	105.2	(45.3-207.3)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	1	4.8	nc	(nc-nc)						
Female	0	1.8	nc	(nc-nc)		Female	16	19.9	80.3	(45.9-130.4)
Lung and Bronchus						All Sites / Types				
Male	37	51.2	72.2	(50.8-99.6)		Male	365	348.4	104.8	(94.3-116.1)

Female 40 43.3 92.4 (66.0-125.8)

Female 345 321.5 107.3 (96.3-119.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

179  
Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	7.1	98.0	(39.2-201.9)	Male	4	3.5	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.2	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	28	26.3	106.5	(70.8-154.0)	Female	1	3.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.1	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
					Female	2	1.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	9	11.0	81.8	(37.3-155.2)					
Female	7	9.8	71.2	(28.5-146.7)	Female	2	2.6	nc	(nc-nc)
Esophagus					Pancreas				
Male	2	1.7	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				

Male	1	0.5	nc	(nc-nc)	Male	30	29.6	101.3	(68.3-144.6)
Female	0	0.4	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	3	2.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Larynx					Testis				
Male	1	1.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
Leukemia					Thyroid				
Male	0	2.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	1.3	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)	Female	9	5.3	169.8	(77.5-322.4)
Lung and Bronchus					All Sites / Types				
Male	15	14.1	106.7	(59.7-176.0)	Male	90	95.1	94.6	(76.1-116.3)
Female	9	11.6	77.7	(35.5-147.6)	Female	83	83.9	99.0	(78.8-122.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

180  
Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	30	31.0	96.8	(65.3-138.2)	Male	13	17.3	75.1	(40.0-128.5)
Female	10	12.3	81.3	(38.9-149.6)	Female	8	14.7	54.3	(23.4-106.9)



Brain and Other Nervous System						Multiple Myeloma				
Male	8	6.9	116.8	(50.3-230.1)		Male	7	4.4	158.3	(63.4-326.2)
Female	3	5.8	nc	(nc-nc)		Female	6	3.8	157.4	(57.5-342.6)
Breast						Non-Hodgkin Lymphoma				
Male	1	1.0	nc	(nc-nc)		Male	12	16.8	71.3	(36.8-124.6)
Female	139	132.3	105.1	(88.3-124.1)		Female	19	15.6	121.6	(73.2-189.8)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	19	12.7	149.1	(89.8-232.9)
Female	5	6.7	74.9	(24.1-174.7)		Female	7	6.4	109.7	(44.0-226.1)
Colon / Rectum						Ovary				
Male	55	48.4	113.7	(85.7-148.0)						
Female	42	50.1	83.8	(60.4-113.2)		Female	14	13.5	103.5	(56.6-173.7)
Esophagus						Pancreas				
Male	5	7.7	64.7	(20.8-150.9)		Male	4	9.0	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)		Female	13	10.4	125.2	(66.6-214.1)
Hodgkin Lymphoma						Prostate				
Male	4	3.3	nc	(nc-nc)		Male	123	128.4	95.8	(79.6-114.3)
Female	3	2.7	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	16	13.1	122.2	(69.8-198.5)		Male	8	8.3	96.6	(41.6-190.4)
Female	7	8.9	78.8	(31.6-162.4)		Female	7	5.4	129.9	(52.1-267.8)
Larynx						Testis				
Male	4	5.8	nc	(nc-nc)		Male	5	6.5	76.4	(24.6-178.2)
Female	1	1.6	nc	(nc-nc)						
Leukemia						Thyroid				
Male	7	10.3	68.2	(27.3-140.5)		Male	4	3.7	nc	(nc-nc)
Female	10	8.9	111.8	(53.5-205.7)		Female	16	11.9	134.8	(77.0-218.9)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	7	6.1	115.5	(46.3-238.0)						

Female	2	2.4	nc	(nc-nc)	Female	24	25.7	93.5	(59.9-139.1)
Lung and Bronchus					All Sites / Types				
Male	71	61.1	116.1	(90.7-146.5)	Male	428	430.2	99.5	(90.3-109.4)
Female	51	56.2	90.8	(67.6-119.4)	Female	425	428.9	99.1	(89.9-109.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

181 Marshfield Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	25	20.1	124.6	(80.6-184.0)	Male	15	11.7	128.4	(71.8-211.9)
Female	12	7.2	165.8	(85.6-289.7)	Female	15	9.8	153.5	(85.9-253.2)
Brain and Other Nervous System					Multiple Myeloma				
Male	10	4.7	214.3	(102.6-394.1)	Male	7	2.9	238.6	(95.6-491.6)
Female	4	3.8	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.7	nc	(nc-nc)	Male	5	11.2	44.7	(14.4-104.2)
Female	87	90.8	95.8	(76.7-118.2)	Female	5	9.6	52.0	(16.8-121.3)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	4.6	nc	(nc-nc)	Male	8	9.1	87.5	(37.7-172.4)
Colon / Rectum					Female	5	4.1	121.2	(39.1-282.9)
Male	40	31.7	126.0	(90.0-171.6)	Ovary				
Female	29	28.4	102.0	(68.3-146.4)	Female	13	9.0	144.4	(76.8-246.9)
Esophagus					Pancreas				

Male	7	5.3	131.5	(52.7-271.0)	Male	9	6.0	149.9	(68.4-284.6)
Female	1	1.4	nc	(nc-nc)	Female	5	5.8	85.8	(27.6-200.2)
Hodgkin Lymphoma					Prostate				
Male	2	2.1	nc	(nc-nc)	Male	116	89.1	130.3	(107.6-156.2)
Female	0	1.7	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	7	5.4	130.3	(52.2-268.4)
Male	7	9.1	76.8	(30.8-158.3)	Female	2	2.9	nc	(nc-nc)
Female	4	5.7	nc	(nc-nc)	Testis				
Larynx					Male	2	3.8	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	Thyroid				
Female	1	1.0	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Leukemia					Female	12	8.2	147.2	(76.0-257.1)
Male	9	6.8	132.1	(60.3-250.7)	Uteri Corpus and Uterus, NOS				
Female	7	5.4	128.5	(51.5-264.8)	Female	22	17.8	123.6	(77.4-187.1)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	2	4.2	nc	(nc-nc)	Male	356	289.4	123.0	(110.5-136.5)
Female	1	1.4	nc	(nc-nc)	Female	283	274.6	103.1	(91.4-115.8)
Lung and Bronchus									
Male	55	40.7	135.1	(101.8-175.9)					
Female	43	35.2	122.0	(88.3-164.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	25	16.3	153.8	(99.5-227.0)		Male	11	7.6	144.4	(72.0-258.5)
Female	5	5.5	91.6	(29.5-213.7)		Female	6	5.8	103.8	(37.9-225.9)
Brain and Other Nervous System						Multiple Myeloma				
Male	3	2.8	nc	(nc-nc)		Male	5	2.2	225.3	(72.6-525.8)
Female	3	2.4	nc	(nc-nc)		Female	2	1.7	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	2	0.5	nc	(nc-nc)		Male	9	7.6	117.8	(53.8-223.6)
Female	89	56.1	158.6	(127.3-195.1)		Female	5	6.7	74.4	(24.0-173.7)
Cervix Uteri						Oral Cavity & Pharynx				
Female	2	2.5	nc	(nc-nc)		Male	7	5.7	123.2	(49.4-253.9)
Colon / Rectum						Female	4	2.7	nc	(nc-nc)
Male	31	24.8	124.9	(84.8-177.3)		Ovary				
Female	21	21.7	96.6	(59.8-147.7)		Female	4	5.7	nc	(nc-nc)
Esophagus						Pancreas				
Male	2	3.8	nc	(nc-nc)		Male	6	4.6	131.0	(47.8-285.2)
Female	3	1.1	nc	(nc-nc)		Female	2	4.6	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	1	1.0	nc	(nc-nc)		Male	106	66.4	159.7	(130.7-193.1)
Female	1	1.0	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	10	4.2	240.1	(115.0-441.6)
Male	8	6.1	130.4	(56.1-256.9)		Female	5	2.3	221.0	(71.2-515.7)
Female	7	3.9	178.1	(71.4-367.0)		Testis				
Larynx						Male	2	1.7	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)		Thyroid				
Female	1	0.7	nc	(nc-nc)		Male	0	1.3	nc	(nc-nc)
Leukemia										
Male	5	4.7	106.0	(34.1-247.3)						

Female	7	3.7	191.5	(76.7-394.5)	Female	3	4.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	5	2.8	176.4	(56.9-411.7)					
Female	1	1.0	nc	(nc-nc)	Female	14	11.3	124.2	(67.8-208.3)
Lung and Bronchus					All Sites / Types				
Male	42	32.0	131.2	(94.6-177.4)	Male	300	212.6	141.1	(125.6-158.0)
Female	29	25.8	112.2	(75.2-161.2)	Female	226	183.4	123.2	(107.7-140.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

183  
Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	8.2	85.8	(34.4-176.7)	Male	11	4.0	272.5	(135.8-487.5)
Female	3	3.0	nc	(nc-nc)	Female	9	3.1	290.5	(132.5-551.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	1.5	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	38	31.0	122.5	(86.7-168.2)	Female	3	3.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.3	nc	(nc-nc)	Male	5	3.1	160.0	(51.6-373.4)
Colon / Rectum					Female	0	1.5	nc	(nc-nc)
					Ovary				

	Male	18	12.6	142.8	(84.6-225.7)					
	Female	12	11.9	100.7	(52.0-176.0)					
Esophagus						Pancreas	Female	2	3.1	nc (nc-nc)
	Male	0	2.0	nc	(nc-nc)		Male	2	2.3	nc (nc-nc)
	Female	1	0.6	nc	(nc-nc)		Female	1	2.5	nc (nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.6	nc	(nc-nc)		Male	29	34.4	84.4 (56.5-121.2)
	Female	1	0.5	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	3	3.2	nc	(nc-nc)		Male	2	2.1	nc (nc-nc)
	Female	2	2.1	nc	(nc-nc)		Female	0	1.2	nc (nc-nc)
Larynx						Testis				
	Male	2	1.5	nc	(nc-nc)		Male	1	0.9	nc (nc-nc)
	Female	0	0.4	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	5	2.4	208.6	(67.2-486.8)		Male	0	0.7	nc (nc-nc)
	Female	1	2.0	nc	(nc-nc)		Female	1	2.2	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	1	1.5	nc	(nc-nc)					
	Female	0	0.6	nc	(nc-nc)		Female	6	6.2	96.4 (35.2-209.9)
Lung and Bronchus						All Sites / Types				
	Male	11	16.1	68.1	(34.0-121.9)		Male	111	109.5	101.4 (83.4-122.1)
	Female	14	13.7	101.9	(55.6-170.9)		Female	104	99.9	104.1 (85.1-126.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Maynard

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	9.9	50.5	(16.3-118.0)	Male	3	5.4	nc	(nc-nc)
Female	6	4.1	147.7	(53.9-321.6)	Female	7	4.7	147.9	(59.3-304.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	2.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.3	nc	(nc-nc)	Male	5	5.2	95.6	(30.8-223.2)
Female	41	43.8	93.7	(67.2-127.1)	Female	13	5.1	252.9	(134.5-432.5)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	2.1	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Colon / Rectum					Female	0	2.1	nc	(nc-nc)
Male	18	15.4	116.8	(69.2-184.7)	Ovary				
Female	13	16.5	78.6	(41.8-134.3)	Female	4	4.5	nc	(nc-nc)
Esophagus					Pancreas				
Male	6	2.5	243.0	(88.7-528.9)	Male	4	2.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	6	3.4	175.3	(64.0-381.6)
Hodgkin Lymphoma					Prostate				
Male	3	0.9	nc	(nc-nc)	Male	34	41.1	82.8	(57.3-115.7)
Female	2	0.8	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	4	2.6	nc	(nc-nc)
Male	5	4.1	120.7	(38.9-281.7)	Female	4	1.8	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Testis				
Larynx					Male	1	1.7	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)					

Leukemia	Female	0	0.5	nc	(nc-nc)
	Male	1	3.2	nc	(nc-nc)
	Female	4	2.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	3	1.9	nc	(nc-nc)
	Female	0	0.8	nc	(nc-nc)
Lung and Bronchus	Male	20	19.4	103.0	(62.9-159.1)
	Female	14	18.8	74.6	(40.8-125.2)

#### Thyroid

Male	1	1.1	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)

#### Uteri Corpus and Uterus, NOS

Female	6	8.5	70.3	(25.7-152.9)
--------	---	-----	------	--------------

#### All Sites / Types

Male	135	136.0	99.3	(83.2-117.5)
Female	144	141.2	102.0	(86.0-120.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

### 185 Medfield

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	10	10.4	96.6	(46.2-177.6)	Male	10	6.0	167.1	(80.0-307.3)
Female	4	3.6	nc	(nc-nc)	Female	10	4.8	208.8	(100.0-384.0)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.3	nc	(nc-nc)	Male	6	5.8	104.0	(38.0-226.3)
Female	50	45.6	109.6	(81.3-144.5)	Female	2	4.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				



Colon / Rectum	Female	2	2.3	nc	(nc-nc)	Male	5	4.8	104.8	(33.8-244.6)
	Male	10	16.4	61.0	(29.2-112.2)	Female	2	2.0	nc	(nc-nc)
Esophagus	Female	18	14.3	125.8	(74.5-198.9)	Female	3	4.5	nc	(nc-nc)
	Male	2	2.8	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	0.7	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
	Male	0	1.0	nc	(nc-nc)	Male	64	45.9	139.4	(107.3-178.0)
Kidney & Renal Pelvis	Female	0	0.8	nc	(nc-nc)	Stomach				
	Male	5	4.7	105.6	(34.0-246.4)	Male	1	2.7	nc	(nc-nc)
Larynx	Female	2	2.9	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
	Male	2	2.1	nc	(nc-nc)	Testis				
Leukemia	Female	0	0.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
	Male	4	3.5	nc	(nc-nc)	Thyroid				
Liver and Intrahepatic Bile Ducts	Female	5	2.8	180.9	(58.3-422.2)	Male	1	1.2	nc	(nc-nc)
	Male	2	2.2	nc	(nc-nc)	Female	6	4.0	151.0	(55.1-328.6)
Lung and Bronchus	Female	2	0.7	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
	Male	17	21.2	80.4	(46.8-128.7)	Female	9	8.8	102.7	(46.9-194.9)
	Female	21	17.4	120.9	(74.8-184.7)	All Sites / Types				
						Male	149	149.2	99.9	(84.5-117.2)
						Female	148	137.0	108.0	(91.3-126.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

186  
Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	67	65.7	102.0	(79.1-129.6)	Male	24	31.8	75.5	(48.4-112.4)
Female	39	27.3	143.0	(101.7-195.6)	Female	18	27.7	64.9	(38.4-102.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	10	11.8	85.1	(40.7-156.4)	Male	11	9.0	122.6	(61.1-219.5)
Female	8	11.1	72.1	(31.0-142.0)	Female	5	8.5	58.9	(19.0-137.5)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.9	nc	(nc-nc)	Male	24	31.9	75.3	(48.2-112.1)
Female	280	259.8	107.8	(95.5-121.2)	Female	37	33.2	111.6	(78.5-153.8)
Cervix Uteri					Oral Cavity & Pharynx				
Female	7	11.8	59.4	(23.8-122.4)	Male	22	22.9	96.2	(60.3-145.7)
Colon / Rectum					Female	16	13.0	123.0	(70.2-199.7)
Male	105	100.2	104.8	(85.7-126.9)	Ovary				
Female	107	112.7	95.0	(77.8-114.8)	Female	27	27.0	99.9	(65.8-145.3)
Esophagus					Pancreas				
Male	13	15.2	85.3	(45.4-145.8)	Male	17	18.5	92.1	(53.6-147.5)
Female	7	5.5	127.4	(51.0-262.5)	Female	14	23.5	59.6	(32.5-99.9)
Hodgkin Lymphoma					Prostate				
Male	5	5.4	92.7	(29.9-216.4)	Male	210	257.7	81.5	(70.8-93.3)
Female	4	5.0	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	26	17.0	152.7	(99.7-223.7)
Male	19	24.6	77.2	(46.5-120.6)					

Larynx	Female	15	18.6	80.8	(45.2-133.3)
	Male	10	11.2	89.6	(42.9-164.7)
Leukemia	Female	6	3.3	184.1	(67.2-400.7)
	Male	24	19.5	123.2	(78.9-183.4)
	Female	24	18.2	132.0	(84.5-196.4)
Liver and Intrahepatic Bile Ducts	Male	11	11.4	96.3	(48.0-172.3)
	Female	7	5.3	133.2	(53.3-274.4)
Lung and Bronchus	Male	145	127.0	114.1	(96.3-134.3)
	Female	121	122.9	98.5	(81.7-117.7)

Testis	Female	15	12.0	124.6	(69.7-205.6)
	Male	11	9.5	115.4	(57.5-206.6)
Thyroid	Male	3	5.9	nc	(nc-nc)
	Female	24	20.1	119.2	(76.4-177.4)
Uteri Corpus and Uterus, NOS	Female	73	51.1	142.7	(111.9-179.5)
All Sites / Types	Male	812	854.5	95.0	(88.6-101.8)
	Female	915	884.5	103.4	(96.9-110.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

187  
Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	15	9.3	162.0	(90.6-267.2)
Female	2	3.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	2.2	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)
Breast				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	9	5.5	165.0	(75.3-313.2)
Female	7	4.7	148.9	(59.7-306.9)
Multiple Myeloma				
Male	0	1.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				

Male	1	0.3	nc	(nc-nc)
Female	41	42.5	96.4	(69.2-130.8)
Cervix Uteri				
Female	2	2.2	nc	(nc-nc)
Colon / Rectum				
Male	20	14.6	136.7	(83.5-211.1)
Female	16	14.1	113.8	(65.0-184.8)
Esophagus				
Male	3	2.4	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	6	4.2	143.3	(52.3-312.0)
Female	2	2.7	nc	(nc-nc)
Larynx				
Male	2	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Leukemia				
Male	1	3.2	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	2.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Lung and Bronchus				
Male	19	18.6	101.9	(61.3-159.2)
Female	18	16.4	109.7	(65.0-173.5)

Male	4	5.2	nc	(nc-nc)
Female	3	4.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	5	4.2	120.0	(38.7-280.0)
Female	2	1.9	nc	(nc-nc)
Ovary				
Female	4	4.2	nc	(nc-nc)
Pancreas				
Male	4	2.8	nc	(nc-nc)
Female	0	2.9	nc	(nc-nc)
Prostate				
Male	47	39.9	117.9	(86.6-156.8)
Stomach				
Male	3	2.5	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Testis				
Male	3	1.9	nc	(nc-nc)
Thyroid				
Male	2	1.2	nc	(nc-nc)
Female	5	4.0	124.8	(40.2-291.2)
Uteri Corpus and Uterus, NOS				
Female	9	8.0	112.1	(51.1-212.8)
All Sites / Types				
Male	156	132.7	117.5	(99.8-137.5)
Female	130	130.8	99.4	(83.0-118.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

188  
Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	35	31.3	111.8	(77.8-155.5)	Male	20	15.6	128.5	(78.4-198.4)
Female	10	13.2	76.0	(36.4-139.8)	Female	18	13.5	133.2	(78.9-210.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	5.7	87.0	(28.0-203.1)	Male	7	4.3	161.5	(64.7-332.8)
Female	8	5.4	147.2	(63.4-290.0)	Female	4	4.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.9	nc	(nc-nc)	Male	24	15.4	155.5	(99.6-231.4)
Female	139	129.1	107.7	(90.5-127.1)	Female	10	16.0	62.6	(30.0-115.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	5.8	nc	(nc-nc)	Male	10	11.6	86.5	(41.4-159.1)
Colon / Rectum					Female	4	6.4	nc	(nc-nc)
Male	56	48.1	116.4	(87.9-151.1)	Ovary				
Female	56	54.7	102.4	(77.4-133.0)	Female	22	13.3	165.2	(103.5-250.1)
Esophagus					Pancreas				
Male	7	7.4	94.0	(37.7-193.7)	Male	11	8.9	123.1	(61.4-220.3)
Female	3	2.7	nc	(nc-nc)	Female	12	11.4	105.5	(54.4-184.3)
Hodgkin Lymphoma					Prostate				
Male	6	2.4	247.8	(90.5-539.3)	Male	159	124.1	128.1	(109.0-149.7)
Female	4	2.2	nc	(nc-nc)					

Kidney & Renal Pelvis					Stomach				
Male	14	12.1	115.5	(63.1-193.8)	Male	9	8.2	109.2	(49.8-207.2)
Female	9	9.0	100.0	(45.6-189.9)	Female	5	5.9	84.8	(27.3-198.0)
Larynx					Testis				
Male	3	5.5	nc	(nc-nc)	Male	5	4.2	118.3	(38.1-276.1)
Female	2	1.6	nc	(nc-nc)					
Leukemia					Thyroid				
Male	10	9.4	106.2	(50.8-195.3)	Male	3	2.9	nc	(nc-nc)
Female	4	8.9	nc	(nc-nc)	Female	8	9.7	82.1	(35.4-161.8)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	3	5.6	nc	(nc-nc)					
Female	4	2.6	nc	(nc-nc)	Female	19	25.2	75.5	(45.4-117.8)
Lung and Bronchus					All Sites / Types				
Male	42	60.4	69.6	(50.1-94.1)	Male	455	411.5	110.6	(100.6-121.2)
Female	49	58.7	83.5	(61.7-110.3)	Female	418	432.0	96.8	(87.7-106.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

189  
Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	4.2	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.0	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)

Breast	Female	0	0.8	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)
Cervix Uteri	Female	19	18.3	103.7	(62.4-161.9)
	Male	6	6.7	89.7	(32.7-195.2)
Colon / Rectum	Female	3	1.0	nc	(nc-nc)
	Male	3	5.8	nc	(nc-nc)
Esophagus	Female	0	0.3	nc	(nc-nc)
	Male	2	1.1	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.4	nc	(nc-nc)
	Male	1	0.4	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	1.1	nc	(nc-nc)
	Male	0	1.9	nc	(nc-nc)
Larynx	Female	0	0.2	nc	(nc-nc)
	Male	1	0.9	nc	(nc-nc)
Leukemia	Female	1	1.1	nc	(nc-nc)
	Male	0	1.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	1	0.3	nc	(nc-nc)
	Male	1	0.9	nc	(nc-nc)
Lung and Bronchus	Female	1	0.3	nc	(nc-nc)
	Male	1	0.4	nc	(nc-nc)

Non-Hodgkin Lymphoma	Female	1	0.4	nc	(nc-nc)
	Male	4	2.4	nc	(nc-nc)
Oral Cavity & Pharynx	Female	4	1.9	nc	(nc-nc)
	Male	0	2.0	nc	(nc-nc)
Ovary	Female	1	0.8	nc	(nc-nc)
	Male	2	1.3	nc	(nc-nc)
Pancreas	Female	0	1.2	nc	(nc-nc)
	Male	18	18.3	98.1	(58.1-155.1)
Prostate	Female	1	0.6	nc	(nc-nc)
	Male	1	1.1	nc	(nc-nc)
Stomach	Female	1	0.8	nc	(nc-nc)
	Male	1	0.8	nc	(nc-nc)
Testis	Female	3	1.7	nc	(nc-nc)
	Male	2	0.5	nc	(nc-nc)
Thyroid	Female	1	3.5	nc	(nc-nc)
	Male	3	1.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	1	3.5	nc	(nc-nc)
	Male	3	1.7	nc	(nc-nc)
All Sites / Types	Female	1	3.5	nc	(nc-nc)
	Male	3	1.7	nc	(nc-nc)

Male	10	8.5	118.0	(56.5-217.0)
Female	8	6.9	116.6	(50.2-229.7)

Male	64	60.7	105.4	(81.2-134.6)
Female	60	55.3	108.4	(82.7-139.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

190  
Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	5.8	154.4	(70.4-293.0)	Male	3	3.2	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	30	24.1	124.5	(84.0-177.7)	Female	4	2.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.2	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Colon / Rectum					Female	0	1.1	nc	(nc-nc)
Male	5	9.1	54.9	(17.7-128.2)	Ovary				
Female	10	8.0	125.5	(60.1-230.9)	Female	1	2.4	nc	(nc-nc)
Esophagus					Pancreas				
Male	3	1.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)



Hodgkin Lymphoma					Prostate				
Male	0	0.5	nc	(nc-nc)	Male	27	24.6	109.8	(72.4-159.8)
Female	0	0.5	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	1	2.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Larynx					Testis				
Male	5	1.1	452.0	(145.7-1054.8)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
Leukemia					Thyroid				
Male	2	1.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	1.2	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	6	4.7	128.4	(46.9-279.4)
Lung and Bronchus					All Sites / Types				
Male	12	11.5	104.0	(53.7-181.7)	Male	78	80.7	96.6	(76.4-120.6)
Female	11	9.7	113.5	(56.6-203.1)	Female	78	74.2	105.1	(83.1-131.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

191  
Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	49	47.3	103.7	(76.7-137.1)	Male	19	23.6	80.6	(48.5-125.9)

Female	24	19.4	123.6	(79.1-183.9)
Brain and Other Nervous System				
Male	16	8.9	179.0	(102.3-290.7)
Female	10	8.2	121.9	(58.3-224.2)
Breast				
Male	4	1.4	nc	(nc-nc)
Female	182	190.7	95.4	(82.1-110.4)
Cervix Uteri				
Female	9	8.7	103.7	(47.3-196.8)
Colon / Rectum				
Male	86	72.4	118.7	(95.0-146.6)
Female	90	80.6	111.7	(89.8-137.3)
Esophagus				
Male	13	11.1	117.0	(62.2-200.0)
Female	6	3.9	153.0	(55.9-333.1)
Hodgkin Lymphoma				
Male	7	3.9	181.1	(72.5-373.1)
Female	6	3.4	175.9	(64.2-382.9)
Kidney & Renal Pelvis				
Male	23	18.3	125.9	(79.8-189.0)
Female	9	13.4	67.1	(30.6-127.4)
Larynx				
Male	4	8.2	nc	(nc-nc)
Female	5	2.3	214.3	(69.0-500.0)
Leukemia				
Male	9	14.5	62.0	(28.3-117.6)
Female	13	13.3	97.7	(52.0-167.0)
Liver and Intrahepatic Bile Ducts				

Female	14	20.0	69.9	(38.2-117.3)
Multiple Myeloma				
Male	10	6.5	152.9	(73.2-281.3)
Female	12	6.1	197.6	(102.0-345.1)
Non-Hodgkin Lymphoma				
Male	21	23.5	89.4	(55.3-136.7)
Female	23	23.8	96.5	(61.2-144.9)
Oral Cavity & Pharynx				
Male	16	17.2	92.8	(53.0-150.8)
Female	11	9.4	117.5	(58.6-210.3)
Ovary				
Female	20	19.7	101.6	(62.0-156.9)
Pancreas				
Male	16	13.4	119.2	(68.1-193.6)
Female	16	16.8	95.5	(54.6-155.1)
Prostate				
Male	199	184.2	108.0	(93.5-124.1)
Stomach				
Male	14	12.4	113.1	(61.8-189.8)
Female	8	8.6	92.9	(40.0-183.1)
Testis				
Male	8	6.7	118.8	(51.1-234.1)
Thyroid				
Male	4	4.4	nc	(nc-nc)
Female	13	14.6	88.9	(47.3-151.9)
Uteri Corpus and Uterus, NOS				

Male	6	8.5	70.4	(25.7-153.3)					
Female	6	3.8	159.9	(58.4-347.9)	Female	47	37.0	127.0	(93.3-168.9)
Lung and Bronchus					All Sites / Types				
Male	82	91.3	89.8	(71.5-111.5)	Male	639	619.2	103.2	(95.3-111.5)
Female	93	87.7	106.1	(85.6-129.9)	Female	660	639.6	103.2	(95.5-111.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

192

#### Middleborough

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	13	16.5	78.7	(41.9-134.6)	Male	6	9.4	64.0	(23.4-139.4)
Female	4	6.5	nc	(nc-nc)	Female	3	8.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	3.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	5	3.2	156.1	(50.3-364.2)	Female	3	2.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.5	nc	(nc-nc)	Male	11	9.1	121.1	(60.3-216.6)
Female	81	72.8	111.3	(88.4-138.3)	Female	8	8.3	96.0	(41.3-189.2)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	3	7.1	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	30	25.9	115.7	(78.0-165.1)					
Female	32	26.4	121.1	(82.8-171.0)	Female	8	7.4	108.3	(46.6-213.4)

Esophagus					Pancreas				
Male	3	4.2	nc	(nc-nc)	Male	6	4.9	123.0	(44.9-267.8)
Female	1	1.3	nc	(nc-nc)	Female	7	5.4	129.0	(51.7-265.8)
Hodgkin Lymphoma					Prostate				
Male	3	1.7	nc	(nc-nc)	Male	72	68.9	104.4	(81.7-131.5)
Female	2	1.5	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	5	7.2	69.6	(22.4-162.4)	Male	6	4.5	134.5	(49.1-292.7)
Female	8	4.7	168.6	(72.6-332.3)	Female	1	2.8	nc	(nc-nc)
Larynx					Testis				
Male	2	3.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)					
Leukemia					Thyroid				
Male	6	5.6	107.6	(39.3-234.2)	Male	1	2.0	nc	(nc-nc)
Female	7	4.8	146.0	(58.5-300.9)	Female	8	6.6	121.1	(52.1-238.6)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	3.3	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)	Female	18	13.9	129.2	(76.5-204.2)
Lung and Bronchus					All Sites / Types				
Male	42	32.7	128.6	(92.7-173.9)	Male	234	231.3	101.2	(88.6-115.0)
Female	38	29.5	128.8	(91.1-176.8)	Female	256	231.1	110.8	(97.6-125.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)
Cervix Uteri				
Female	0	0.1	nc	(nc-nc)
Colon / Rectum				
Male	0	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Esophagus				
Male	0	0.1	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Larynx				
Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Leukemia				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Ovary				
Female	1	0.2	nc	(nc-nc)
Pancreas				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Prostate				
Male	2	2.1	nc	(nc-nc)
Stomach				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Testis				
Male	0	0.1	nc	(nc-nc)
Thyroid				

Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Lung and Bronchus				
Male	2	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	0.4	nc	(nc-nc)
All Sites / Types				
Male	4	7.1	nc	(nc-nc)
Female	4	6.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

194  
Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	11	6.7	164.3	(81.9-294.0)
Female	3	2.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	42	25.8	162.8	(117.3-220.1)
Cervix Uteri				
Female	1	1.2	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	4	3.9	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	3.8	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	4	2.9	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)

Colon / Rectum					Ovary				
Male	7	10.5	66.6	(26.7-137.2)					
Female	11	8.8	125.3	(62.4-224.1)	Female	1	2.6	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	1.7	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	3	0.8	nc	(nc-nc)	Male	24	28.0	85.7	(54.9-127.5)
Female	0	0.5	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	2	2.9	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Larynx					Testis				
Male	3	1.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
Leukemia					Thyroid				
Male	4	2.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	1.4	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	21	13.3	158.2	(97.9-241.8)	Male	106	94.5	112.2	(91.8-135.7)
Female	13	10.8	120.6	(64.1-206.2)	Female	100	80.3	124.5	(101.3-151.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	34	25.4	133.9	(92.7-187.1)	Male	11	13.5	81.7	(40.7-146.3)
Female	7	10.2	68.6	(27.5-141.4)	Female	17	11.5	148.4	(86.4-237.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	5.2	95.9	(30.9-223.8)	Male	2	3.6	nc	(nc-nc)
Female	7	4.6	151.9	(60.9-313.0)	Female	4	3.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.8	nc	(nc-nc)	Male	17	13.2	128.7	(74.9-206.1)
Female	97	105.8	91.6	(74.3-111.8)	Female	16	12.8	125.2	(71.5-203.3)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	5.1	nc	(nc-nc)	Male	10	10.0	100.1	(47.9-184.1)
					Female	9	5.1	175.5	(80.1-333.1)
Colon / Rectum					Ovary				
Male	41	39.3	104.3	(74.8-141.4)					
Female	38	42.2	90.1	(63.7-123.7)	Female	10	10.9	91.9	(44.0-169.0)
Esophagus					Pancreas				
Male	6	6.2	96.9	(35.4-210.9)	Male	5	7.3	68.2	(22.0-159.1)
Female	0	2.1	nc	(nc-nc)	Female	8	8.7	91.8	(39.5-180.8)
Hodgkin Lymphoma					Prostate				
Male	0	2.4	nc	(nc-nc)	Male	102	102.5	99.6	(81.2-120.8)
Female	2	2.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	11	10.4	106.2	(52.9-190.0)	Male	10	6.7	148.9	(71.3-273.9)
Female	5	7.2	69.4	(22.4-161.9)	Female	5	4.5	110.7	(35.7-258.3)
Larynx					Testis				



Male	7	4.6	151.4	(60.7-312.0)
Female	1	1.3	nc	(nc-nc)
Leukemia				
Male	3	8.1	nc	(nc-nc)
Female	7	7.3	96.2	(38.6-198.3)
Liver and Intrahepatic Bile Ducts				
Male	6	4.8	124.5	(45.4-270.9)
Female	4	2.0	nc	(nc-nc)
Lung and Bronchus				
Male	58	49.6	116.9	(88.8-151.1)
Female	49	46.2	106.1	(78.5-140.3)

Male	1	4.3	nc	(nc-nc)
Thyroid				
Male	3	2.7	nc	(nc-nc)
Female	7	8.8	79.2	(31.7-163.1)
Uteri Corpus and Uterus, NOS				
Female	19	20.5	92.5	(55.7-144.4)
All Sites / Types				
Male	347	343.3	101.1	(90.7-112.3)
Female	339	347.8	97.5	(87.4-108.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

196  
Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	18	14.5	124.2	(73.6-196.3)
Female	3	5.8	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	2.7	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	51	57.7	88.4	(65.8-116.2)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	4	7.2	nc	(nc-nc)
Female	2	6.0	nc	(nc-nc)
Multiple Myeloma				
Male	0	2.0	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	3	7.2	nc	(nc-nc)
Female	8	7.1	112.8	(48.6-222.3)

Cervix Uteri					Oral Cavity & Pharynx						
	Male	5	5.4	92.1	(29.7-215.0)		Female	3	2.8	nc	(nc-nc)
	Female	2	2.6	nc	(nc-nc)	Ovary					
Colon / Rectum						Pancreas					
	Male	16	22.3	71.7	(40.9-116.4)		Female	8	5.9	134.5	(57.9-265.0)
	Female	11	23.9	46.1	(23.0-82.5)	Prostate					
Esophagus						Stomach					
	Male	5	3.5	143.4	(46.2-334.5)		Male	2	4.1	nc	(nc-nc)
	Female	2	1.2	nc	(nc-nc)		Female	7	5.0	140.5	(56.3-289.4)
Hodgkin Lymphoma						Testis					
	Male	1	1.1	nc	(nc-nc)		Male	57	58.5	97.4	(73.7-126.2)
	Female	1	1.0	nc	(nc-nc)	Thyroid					
Kidney & Renal Pelvis						Uteri Corpus and Uterus, NOS					
	Male	3	5.7	nc	(nc-nc)		Female	20	11.4	175.3	(107.0-270.7)
	Female	6	4.0	148.8	(54.3-324.0)	All Sites / Types					
Larynx						All Sites / Types					
	Male	6	2.6	232.8	(85.0-506.8)		Male	179	192.4	93.1	(79.9-107.7)
	Female	1	0.7	nc	(nc-nc)		Female	181	192.2	94.2	(80.9-108.9)
Leukemia											
	Male	3	4.4	nc	(nc-nc)						
	Female	3	3.9	nc	(nc-nc)						
Liver and Intrahepatic Bile Ducts											
	Male	0	2.6	nc	(nc-nc)						
	Female	3	1.1	nc	(nc-nc)						
Lung and Bronchus											
	Male	38	28.2	134.9	(95.4-185.1)						
	Female	35	26.4	132.6	(92.4-184.5)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

197 Millis									
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	13	6.4	204.1	(108.6-349.1)	Male	3	3.7	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	6	3.2	190.2	(69.5-414.0)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	1.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	37	28.9	128.2	(90.3-176.8)	Female	2	3.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.5	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
					Female	1	1.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	13	10.1	128.9	(68.5-220.4)					
Female	10	8.9	112.4	(53.8-206.7)	Female	2	2.8	nc	(nc-nc)
Esophagus					Pancreas				
Male	4	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	0.7	nc	(nc-nc)	Male	32	28.3	112.9	(77.2-159.4)
Female	0	0.6	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	3	2.9	nc	(nc-nc)	Testis	Male	0	1.7	nc	(nc-nc)
	Female	3	1.8	nc	(nc-nc)		Female	2	0.9	nc	(nc-nc)
Leukemia	Male	0	1.3	nc	(nc-nc)	Thyroid	Male	4	1.3	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)		Female	1	2.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	3	2.2	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Male	0	0.8	nc	(nc-nc)
	Female	0	1.7	nc	(nc-nc)		Female	3	5.6	nc	(nc-nc)
Lung and Bronchus	Male	0	1.4	nc	(nc-nc)	All Sites / Types	Male	104	92.3	112.7	(92.1-136.5)
	Female	0	0.4	nc	(nc-nc)		Female	103	87.0	118.4	(96.6-143.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

198  
Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	1.8	276.7	(89.2-645.8)	Male	2	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.5	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
	Male	0	0.1	nc	(nc-nc)		Male	0	1.1	nc (nc-nc)
	Female	8	8.4	95.1	(41.0-187.5)		Female	0	0.9	nc (nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
	Female	2	0.5	nc	(nc-nc)		Male	1	0.8	nc (nc-nc)
							Female	0	0.4	nc (nc-nc)
Colon / Rectum						Ovary				
	Male	3	2.9	nc	(nc-nc)					
	Female	4	2.8	nc	(nc-nc)		Female	1	0.8	nc (nc-nc)
Esophagus						Pancreas				
	Male	0	0.5	nc	(nc-nc)		Male	0	0.5	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.6	nc (nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.2	nc	(nc-nc)		Male	7	7.8	89.6 (35.9-184.6)
	Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	2	0.8	nc	(nc-nc)		Male	0	0.5	nc (nc-nc)
	Female	0	0.5	nc	(nc-nc)		Female	0	0.3	nc (nc-nc)
Larynx						Testis				
	Male	0	0.4	nc	(nc-nc)		Male	0	0.5	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	3	0.7	nc	(nc-nc)		Male	0	0.3	nc (nc-nc)
	Female	1	0.5	nc	(nc-nc)		Female	0	0.9	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.4	nc	(nc-nc)					
	Female	0	0.1	nc	(nc-nc)		Female	5	1.6	315.7 (101.8-736.8)
Lung and Bronchus						All Sites / Types				
	Male	6	3.7	163.8	(59.8-356.5)		Male	33	26.4	125.1 (86.1-175.8)

Female	4	3.3	nc	(nc-nc)	Female	33	26.2	125.9	(86.7-176.8)
--------	---	-----	----	---------	--------	----	------	-------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

199  
Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	21	30.8	68.1	(42.1-104.1)	Male	25	15.1	166.1	(107.4-245.2)
Female	13	12.5	103.8	(55.2-177.6)	Female	13	12.7	102.5	(54.5-175.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	5.6	nc	(nc-nc)	Male	5	4.3	117.3	(37.8-273.8)
Female	8	5.2	154.0	(66.3-303.4)	Female	1	3.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.9	nc	(nc-nc)	Male	15	15.0	99.7	(55.8-164.5)
Female	121	123.8	97.8	(81.1-116.8)	Female	18	15.2	118.5	(70.2-187.3)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	5.4	nc	(nc-nc)	Male	10	11.2	89.2	(42.7-164.0)
Colon / Rectum					Female	5	6.1	82.6	(26.6-192.8)
Male	49	47.2	103.7	(76.7-137.1)	Ovary				
Female	62	52.0	119.2	(91.4-152.8)	Female	13	12.7	102.1	(54.3-174.6)
Esophagus					Pancreas				
Male	4	7.3	nc	(nc-nc)	Male	10	8.8	114.2	(54.7-209.9)
Female	2	2.5	nc	(nc-nc)	Female	11	10.8	101.7	(50.7-181.9)
Hodgkin Lymphoma					Prostate				

Male	2	2.3	nc	(nc-nc)	Male	135	120.9	111.6	(93.6-132.1)
Female	1	2.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	8	11.8	67.8	(29.2-133.5)	Male	7	8.1	86.5	(34.7-178.3)
Female	7	8.6	81.1	(32.5-167.1)	Female	4	5.6	nc	(nc-nc)
Larynx					Testis				
Male	6	5.3	112.5	(41.1-244.9)	Male	3	3.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)					
Leukemia					Thyroid				
Male	11	9.3	118.7	(59.2-212.4)	Male	2	2.7	nc	(nc-nc)
Female	6	8.5	70.4	(25.7-153.2)	Female	8	9.0	88.5	(38.1-174.3)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	4	5.5	nc	(nc-nc)					
Female	2	2.4	nc	(nc-nc)	Female	18	24.1	74.8	(44.3-118.2)
Lung and Bronchus					All Sites / Types				
Male	33	59.4	55.5	(38.2-78.0)	Male	374	402.1	93.0	(83.8-102.9)
Female	52	56.1	92.6	(69.2-121.5)	Female	402	412.1	97.6	(88.2-107.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

200  
Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)

Brain and Other Nervous System						Multiple Myeloma				
	Male	0	0.0	nc	(nc-nc)		Male	0	0.0	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.0	nc (nc-nc)
Breast						Non-Hodgkin Lymphoma				
	Male	0	0.0	nc	(nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	2	0.5	nc	(nc-nc)		Female	0	0.1	nc (nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
							Male	0	0.0	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.0	nc (nc-nc)
Colon / Rectum						Ovary				
	Male	0	0.2	nc	(nc-nc)					
	Female	0	0.2	nc	(nc-nc)		Female	0	0.0	nc (nc-nc)
Esophagus						Pancreas				
	Male	0	0.0	nc	(nc-nc)		Male	0	0.0	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.0	nc (nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.0	nc	(nc-nc)		Male	1	0.5	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	1	0.0	nc	(nc-nc)		Male	0	0.0	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.0	nc (nc-nc)
Larynx						Testis				
	Male	0	0.0	nc	(nc-nc)		Male	0	0.0	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.0	nc	(nc-nc)		Male	0	0.0	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.0	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.0	nc	(nc-nc)					



Female	0	0.0	nc	(nc-nc)
Lung and Bronchus				
Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Female	0	0.1	nc	(nc-nc)
All Sites / Types				
Male	2	1.5	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

201  
Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	12	8.2	147.1	(75.9-257.0)
Female	6	2.9	207.2	(75.7-451.1)
Brain and Other Nervous System				
Male	1	1.8	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	31	34.2	90.7	(61.6-128.8)
Cervix Uteri				
Female	1	1.7	nc	(nc-nc)
Colon / Rectum				
Male	7	12.8	54.6	(21.9-112.5)
Female	10	11.6	86.6	(41.4-159.2)
Esophagus				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	8	4.6	173.8	(74.8-342.4)
Female	1	3.6	nc	(nc-nc)
Multiple Myeloma				
Male	1	1.2	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	4.4	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	3.6	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)
Ovary				
Female	3	3.4	nc	(nc-nc)
Pancreas				

Hodgkin Lymphoma	Male	2	2.1	nc	(nc-nc)	Prostate	Male	1	2.4	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)		Female	1	2.4	nc	(nc-nc)
Kidney & Renal Pelvis	Male	2	0.8	nc	(nc-nc)	Stomach	Male	34	35.4	96.0	(66.4-134.1)
	Female	1	0.6	nc	(nc-nc)		Female	4	1.2	nc	(nc-nc)
Larynx	Male	0	1.6	nc	(nc-nc)	Testis	Male	0	1.4	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	6	2.9	203.7	(74.4-443.3)
Leukemia	Male	2	2.7	nc	(nc-nc)	Thyroid	Male	1	0.9	nc	(nc-nc)
	Female	1	2.1	nc	(nc-nc)		Female	5	6.7	74.8	(24.1-174.6)
Liver and Intrahepatic Bile Ducts	Male	2	1.7	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Male	98	115.4	84.9	(68.9-103.5)
	Female	1	0.6	nc	(nc-nc)		Female	107	105.7	101.2	(82.9-122.3)
Lung and Bronchus	Male	14	16.5	85.1	(46.5-142.7)	All Sites / Types					
	Female	16	13.8	115.5	(66.0-187.6)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	8	9.6	83.7	(36.1-165.0)		Male	5	4.7	105.5	(34.0-246.3)
Female	3	3.9	nc	(nc-nc)		Female	3	3.9	nc	(nc-nc)
Brain and Other Nervous System						Multiple Myeloma				
Male	4	1.8	nc	(nc-nc)		Male	1	1.3	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)		Female	1	1.2	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	1	0.3	nc	(nc-nc)		Male	8	4.7	169.7	(73.1-334.4)
Female	34	38.0	89.4	(61.9-124.9)		Female	8	4.7	168.7	(72.6-332.4)
Cervix Uteri						Oral Cavity & Pharynx				
Female	1	1.7	nc	(nc-nc)		Male	3	3.5	nc	(nc-nc)
Colon / Rectum						Female	3	1.9	nc	(nc-nc)
Male	14	14.7	95.6	(52.2-160.3)		Ovary				
Female	9	15.8	56.8	(25.9-107.8)		Female	4	3.9	nc	(nc-nc)
Esophagus						Pancreas				
Male	3	2.3	nc	(nc-nc)		Male	3	2.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)		Female	3	3.3	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.7	nc	(nc-nc)		Male	38	37.7	100.8	(71.3-138.4)
Female	1	0.7	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	0	2.5	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)		Female	1	1.7	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)		Testis				
Larynx						Male	2	1.3	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)		Thyroid				
Female	2	0.5	nc	(nc-nc)		Male	0	0.9	nc	(nc-nc)
Leukemia										
Male	4	2.9	nc	(nc-nc)						

Female	2	2.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	1.7	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)	Female	6	7.5	80.2	(29.3-174.5)
Lung and Bronchus					All Sites / Types				
Male	22	18.6	118.2	(74.0-178.9)	Male	130	125.4	103.6	(86.6-123.1)
Female	10	17.9	55.9	(26.8-102.9)	Female	106	127.2	83.3	(68.2-100.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

203  
Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	1.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
					Female	0	0.2	nc	(nc-nc)
Colon / Rectum					Ovary				

Esophagus	Male	1	2.1	nc	(nc-nc)	Pancreas	Female	0	0.4	nc	(nc-nc)
	Female	2	1.5	nc	(nc-nc)						
Hodgkin Lymphoma	Male	0	0.3	nc	(nc-nc)	Prostate	Male	0	0.4	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	1	0.3	nc	(nc-nc)
Kidney & Renal Pelvis	Male	0	0.1	nc	(nc-nc)	Stomach	Male	7	5.8	120.3	(48.2-247.9)
	Female	0	0.1	nc	(nc-nc)						
Larynx	Male	0	0.5	nc	(nc-nc)	Testis	Male	0	0.4	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
Leukemia	Male	0	0.3	nc	(nc-nc)	Thyroid	Male	1	0.1	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)						
Liver and Intrahepatic Bile Ducts	Male	0	0.4	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Male	0	0.1	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Lung and Bronchus	Male	0	0.3	nc	(nc-nc)	All Sites / Types	Female	1	0.9	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)						
	Male	2	2.7	nc	(nc-nc)		Male	14	18.3	76.7	(41.9-128.7)
	Female	2	1.9	nc	(nc-nc)		Female	8	13.8	57.8	(24.9-113.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Colon / Rectum					Female	0	0.1	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	Ovary				
Female	0	1.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	0.1	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Testis				
Larynx					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)					

Female	0	0.0	nc	(nc-nc)	Thyroid				
Leukemia					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Liver and Intrahepatic Bile Ducts					Female	0	0.6	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	All Sites / Types				
Female	0	0.0	nc	(nc-nc)	Male	11	11.1	99.5	(49.6-178.0)
Lung and Bronchus					Female	9	8.9	100.8	(46.0-191.4)
Male	1	1.6	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

205  
Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				

Colon / Rectum	Female	0	0.0	nc	(nc-nc)	Ovary	Male	0	0.1	nc	(nc-nc)
	Male	0	0.4	nc	(nc-nc)		Female	0	0.0	nc	(nc-nc)
Esophagus	Female	1	0.3	nc	(nc-nc)	Pancreas	Female	0	0.1	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.0	nc	(nc-nc)	Prostate	Female	0	0.1	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)		Male	3	1.2	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.0	nc	(nc-nc)	Stomach	Male	0	0.1	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)		Female	1	0.0	nc	(nc-nc)
Larynx	Female	0	0.1	nc	(nc-nc)	Testis	Male	0	0.0	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)		Female	0	0.0	nc	(nc-nc)
Leukemia	Female	0	0.0	nc	(nc-nc)	Thyroid	Male	0	0.0	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)		Female	0	0.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	0	0.0	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Female	0	0.2	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)		Male	3	3.7	nc	(nc-nc)
Lung and Bronchus	Female	0	0.4	nc	(nc-nc)	All Sites / Types	Female	3	2.5	nc	(nc-nc)
	Male	0	0.5	nc	(nc-nc)		Male	3	3.7	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;



- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

206  
Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	5.6	124.6	(49.9-256.7)	Male	5	2.6	189.3	(61.0-441.7)
Female	3	1.9	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	0.9	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	21	19.3	108.8	(67.4-166.4)	Female	1	2.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.8	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Colon / Rectum					Female	2	0.9	nc	(nc-nc)
Male	11	8.6	128.3	(64.0-229.6)	Ovary				
Female	1	7.9	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Esophagus					Pancreas				
Male	2	1.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.3	nc	(nc-nc)	Male	24	21.7	110.7	(70.9-164.7)
Female	0	0.3	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	1	1.5	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)					

Larynx	Female	1	1.3	nc	(nc-nc)	Testis	Female	1	0.8	nc	(nc-nc)
	Male	0	1.0	nc	(nc-nc)		Male	1	0.5	nc	(nc-nc)
Leukemia	Female	0	0.2	nc	(nc-nc)	Thyroid					
	Male	0	1.6	nc	(nc-nc)		Male	0	0.4	nc	(nc-nc)
	Female	0	1.3	nc	(nc-nc)		Female	2	1.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	1.0	nc	(nc-nc)						
	Female	0	0.4	nc	(nc-nc)		Female	1	3.8	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	7	10.7	65.4	(26.2-134.8)		Male	79	71.8	110.0	(87.1-137.1)
	Female	9	8.7	103.6	(47.3-196.6)		Female	64	63.4	100.9	(77.7-128.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

207  
Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	8	8.3	96.8	(41.7-190.7)	Male	8	4.7	169.6	(73.0-334.2)
Female	6	2.9	203.6	(74.3-443.1)	Female	12	3.7	320.8	(165.6-560.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	4	0.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Male	0	0.3	nc	(nc-nc)
Female	45	33.2	135.4	(98.7-181.2)
Cervix Uteri				
Female	1	1.7	nc	(nc-nc)
Colon / Rectum				
Male	14	13.0	108.1	(59.0-181.4)
Female	8	11.9	67.4	(29.0-132.8)
Esophagus				
Male	1	2.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	3.6	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)
Larynx				
Male	0	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Leukemia				
Male	4	2.7	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Lung and Bronchus				
Male	18	16.4	109.8	(65.0-173.5)
Female	15	13.8	109.0	(61.0-179.8)

Male	5	4.5	110.2	(35.5-257.1)
Female	5	3.8	130.8	(42.2-305.3)
Oral Cavity & Pharynx				
Male	3	3.5	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)
Ovary				
Female	4	3.4	nc	(nc-nc)
Pancreas				
Male	2	2.4	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)
Prostate				
Male	46	34.5	133.4	(97.6-177.9)
Stomach				
Male	2	2.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Testis				
Male	4	1.7	nc	(nc-nc)
Thyroid				
Male	1	1.0	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	4	6.4	nc	(nc-nc)
All Sites / Types				
Male	125	115.6	108.1	(90.0-128.8)
Female	128	105.6	121.2	(101.1-144.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

208  
Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	33	33.6	98.1	(67.5-137.8)	Male	30	17.4	172.2	(116.2-245.9)
Female	14	13.3	105.2	(57.5-176.5)	Female	13	14.9	87.0	(46.3-148.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	6	6.6	90.4	(33.0-196.8)	Male	4	4.7	nc	(nc-nc)
Female	8	5.9	134.9	(58.1-265.7)	Female	3	4.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.0	nc	(nc-nc)	Male	18	17.1	105.3	(62.4-166.4)
Female	160	139.6	114.6	(97.6-133.8)	Female	17	16.7	102.1	(59.4-163.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	6	6.7	89.8	(32.8-195.5)	Male	17	13.0	131.2	(76.4-210.1)
Colon / Rectum					Female	11	6.7	163.4	(81.4-292.3)
Male	59	52.0	113.5	(86.4-146.4)	Ovary				
Female	44	54.2	81.2	(59.0-109.0)	Female	20	14.2	140.6	(85.8-217.1)
Esophagus					Pancreas				
Male	11	8.2	133.9	(66.7-239.5)	Male	10	9.7	103.6	(49.6-190.5)
Female	5	2.6	189.1	(60.9-441.2)	Female	8	11.3	71.0	(30.6-140.0)
Hodgkin Lymphoma					Prostate				
Male	1	2.9	nc	(nc-nc)	Male	144	139.2	103.5	(87.3-121.8)
Female	4	2.5	nc	(nc-nc)					

Kidney & Renal Pelvis					Stomach				
Male	12	13.6	88.3	(45.6-154.2)	Male	7	8.8	79.7	(31.9-164.1)
Female	13	9.5	136.5	(72.6-233.5)	Female	4	5.8	nc	(nc-nc)
Larynx					Testis				
Male	6	6.1	98.1	(35.8-213.5)	Male	8	5.3	151.9	(65.4-299.4)
Female	1	1.7	nc	(nc-nc)					
Leukemia					Thyroid				
Male	12	10.5	114.6	(59.1-200.2)	Male	6	3.4	176.0	(64.3-383.2)
Female	14	9.3	150.3	(82.1-252.1)	Female	15	11.5	130.8	(73.1-215.7)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	5	6.3	79.3	(25.6-185.1)					
Female	1	2.6	nc	(nc-nc)	Female	30	27.2	110.1	(74.3-157.2)
Lung and Bronchus					All Sites / Types				
Male	57	66.5	85.7	(64.9-111.0)	Male	486	455.3	106.7	(97.5-116.7)
Female	72	61.4	117.2	(91.7-147.6)	Female	496	454.9	109.0	(99.6-119.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

209  
Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	31	36.6	84.8	(57.6-120.4)	Male	28	17.5	160.0	(106.3-231.2)
Female	17	14.7	115.6	(67.3-185.1)	Female	18	14.3	125.6	(74.4-198.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	10	6.4	155.1	(74.3-285.3)	Male	3	5.0	nc	(nc-nc)

Breast	Female	9	5.9	152.3	(69.5-289.1)
	Male	1	1.1	nc	(nc-nc)
Cervix Uteri	Female	167	141.8	117.8	(100.6-137.1)
Colon / Rectum	Female	1	6.1	nc	(nc-nc)
	Male	47	55.9	84.0	(61.7-111.7)
Esophagus	Female	48	61.5	78.1	(57.6-103.5)
	Male	6	8.6	69.6	(25.4-151.4)
Hodgkin Lymphoma	Female	3	3.0	nc	(nc-nc)
	Male	1	2.5	nc	(nc-nc)
Kidney & Renal Pelvis	Female	3	2.2	nc	(nc-nc)
	Male	18	13.9	129.4	(76.7-204.6)
Larynx	Female	6	9.9	60.5	(22.1-131.6)
	Male	1	6.3	nc	(nc-nc)
Leukemia	Female	1	1.7	nc	(nc-nc)
	Male	10	10.8	92.6	(44.3-170.3)
Liver and Intrahepatic Bile Ducts	Female	11	10.0	110.3	(55.0-197.4)
	Male	3	6.5	nc	(nc-nc)
Lung and Bronchus	Female	7	2.9	244.4	(97.9-503.6)

Non-Hodgkin Lymphoma	Female	5	4.5	110.0	(35.4-256.6)
	Male	11	17.5	62.9	(31.3-112.5)
Oral Cavity & Pharynx	Female	17	17.5	97.2	(56.6-155.7)
	Male	8	13.1	60.9	(26.2-119.9)
Ovary	Female	2	7.0	nc	(nc-nc)
Pancreas	Female	16	14.6	109.3	(62.4-177.5)
	Male	6	10.4	57.8	(21.1-125.9)
Prostate	Female	17	12.8	132.8	(77.3-212.6)
	Male	182	144.6	125.9	(108.3-145.6)
Stomach	Male	5	9.6	52.2	(16.8-121.8)
	Female	3	6.7	nc	(nc-nc)
Testis	Male	4	3.8	nc	(nc-nc)
Thyroid	Male	9	3.0	296.5	(135.3-562.9)
	Female	12	9.9	121.7	(62.8-212.7)
Uteri Corpus and Uterus, NOS	Female	22	27.7	79.3	(49.7-120.1)
All Sites / Types					

Male	41	70.5	58.1	(41.7-78.9)	Male	443	475.0	93.3	(84.8-102.4)
Female	64	64.6	99.1	(76.3-126.5)	Female	485	476.1	101.9	(93.0-111.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

210

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
					Female	0	0.0	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	0	0.4	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)

Hodgkin Lymphoma					Prostate				
Male	0	0.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Larynx					Testis				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
Leukemia					Thyroid				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.1	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	0	0.5	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	93	106.9	87.0	(70.2-106.6)	Male	28	51.1	54.8	(36.4-79.2)



Female	39	45.0	86.6	(61.6-118.4)
Brain and Other Nervous System				
Male	22	19.3	114.0	(71.4-172.7)
Female	11	18.4	59.9	(29.8-107.1)
Breast				
Male	3	3.1	nc	(nc-nc)
Female	343	419.8	81.7	(73.3-90.8)
Cervix Uteri				
Female	23	18.5	124.4	(78.8-186.6)
Colon / Rectum				
Male	178	162.9	109.3	(93.8-126.6)
Female	177	187.2	94.6	(81.2-109.6)
Esophagus				
Male	31	24.7	125.6	(85.3-178.3)
Female	7	9.1	76.8	(30.8-158.2)
Hodgkin Lymphoma				
Male	11	8.4	131.5	(65.6-235.4)
Female	15	7.8	192.9	(107.9-318.2)
Kidney & Renal Pelvis				
Male	51	39.8	128.1	(95.3-168.4)
Female	30	30.4	98.8	(66.7-141.1)
Larynx				
Male	23	18.0	127.5	(80.8-191.3)
Female	5	5.3	94.4	(30.4-220.2)
Leukemia				
Male	33	32.1	102.7	(70.7-144.3)
Female	36	30.5	118.1	(82.7-163.5)
Liver and Intrahepatic Bile Ducts				

Female	20	44.1	45.3	(27.7-70.0)
Multiple Myeloma				
Male	21	14.6	144.2	(89.2-220.4)
Female	12	14.0	85.6	(44.2-149.5)
Non-Hodgkin Lymphoma				
Male	36	51.5	70.0	(49.0-96.9)
Female	44	54.3	81.0	(58.9-108.8)
Oral Cavity & Pharynx				
Male	42	37.0	113.6	(81.9-153.6)
Female	21	21.2	99.2	(61.4-151.7)
Ovary				
Female	48	43.9	109.4	(80.6-145.0)
Pancreas				
Male	33	30.0	109.8	(75.6-154.3)
Female	50	39.1	128.0	(95.0-168.7)
Prostate				
Male	390	414.6	94.1	(85.0-103.9)
Stomach				
Male	48	27.8	172.9	(127.5-229.3)
Female	25	20.1	124.6	(80.6-184.0)
Testis				
Male	16	14.1	113.3	(64.7-184.0)
Thyroid				
Male	12	9.2	130.8	(67.5-228.5)
Female	23	31.1	73.9	(46.9-111.0)
Uteri Corpus and Uterus, NOS				

Male	27	18.5	145.8	(96.1-212.1)					
Female	14	8.7	160.7	(87.8-269.6)	Female	81	82.6	98.0	(77.8-121.8)
Lung and Bronchus					All Sites / Types				
Male	249	205.5	121.2	(106.6-137.2)	Male	1415	1381.4	102.4	(97.2-107.9)
Female	139	201.2	69.1	(58.1-81.6)	Female	1263	1443.6	87.5	(82.7-92.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

212

#### New Braintree

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	2	1.2	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)

Esophagus						Pancreas					
	Male	0	0.2	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma						Prostate					
	Male	0	0.1	nc	(nc-nc)		Male	5	3.1	160.3	(51.6-374.0)
	Female	0	0.1	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach					
	Male	0	0.4	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
Larynx						Testis					
	Male	0	0.2	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	0	0.3	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.2	nc	(nc-nc)						
	Female	0	0.1	nc	(nc-nc)		Female	1	0.6	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	1	1.5	nc	(nc-nc)		Male	14	10.9	128.4	(70.1-215.4)
	Female	0	1.3	nc	(nc-nc)		Female	9	10.1	88.9	(40.6-168.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	1.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	6.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
					Female	1	0.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	2	3.0	nc	(nc-nc)					
Female	2	2.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	2	8.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Larynx					Testis				
Male	0	0.4	nc	(nc-nc)	Male	2	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Leukemia					Thyroid				

Male	0	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.4	nc	(nc-nc)					
Female	1	0.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	1	3.8	nc	(nc-nc)	Male	9	25.9	34.7	(15.8-65.9)
Female	2	2.9	nc	(nc-nc)	Female	14	21.0	66.8	(36.5-112.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

214 New Salem									
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)

Colon / Rectum						Ovary				
Male	0	1.6	nc	(nc-nc)						
Female	1	1.2	nc	(nc-nc)		Female	1	0.4	nc	(nc-nc)
Esophagus						Pancreas				
Male	0	0.3	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.1	nc	(nc-nc)		Male	6	4.5	133.4	(48.7-290.5)
Female	0	0.1	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	0	0.5	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
Larynx						Testis				
Male	1	0.2	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)						
Leukemia						Thyroid				
Male	0	0.3	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)		Female	1	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	0.2	nc	(nc-nc)						
Female	0	0.1	nc	(nc-nc)		Female	0	0.7	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	1	2.1	nc	(nc-nc)		Male	11	14.4	76.2	(38.0-136.3)
Female	1	1.4	nc	(nc-nc)		Female	7	11.0	63.5	(25.4-130.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



Male	0	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
Leukemia					Thyroid				
Male	1	2.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	1.3	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	8	5.4	147.6	(63.6-290.9)
Lung and Bronchus					All Sites / Types				
Male	13	12.9	100.6	(53.5-172.0)	Male	99	90.7	109.2	(88.7-132.9)
Female	10	11.1	90.4	(43.3-166.2)	Female	98	85.4	114.7	(93.1-139.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

216  
Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	25	17.8	140.2	(90.7-206.9)	Male	10	9.6	104.7	(50.1-192.5)
Female	8	7.4	108.2	(46.6-213.2)	Female	20	8.5	236.6	(144.5-365.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	3.6	140.4	(45.2-327.6)	Male	2	2.5	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)	Male	13	9.3	140.3	(74.6-239.9)
Female	98	80.6	121.6	(98.7-148.2)	Female	13	9.2	140.9	(75.0-241.0)



Cervix Uteri						Oral Cavity & Pharynx					
	Male	7	7.3	95.4	(38.2-196.6)		Male	7	7.3	95.4	(38.2-196.6)
	Female	3	3.8	nc	(nc-nc)		Female	3	3.8	nc	(nc-nc)
Colon / Rectum						Ovary					
	Male	35	27.8	125.9	(87.7-175.1)						
	Female	39	30.3	128.8	(91.6-176.0)						
Esophagus						Pancreas					
	Male	5	4.5	111.8	(36.0-260.8)						
	Female	2	1.5	nc	(nc-nc)						
Hodgkin Lymphoma						Prostate					
	Male	3	1.5	nc	(nc-nc)						
	Female	2	1.3	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach					
	Male	7	7.5	93.9	(37.6-193.4)						
	Female	11	5.3	207.1	(103.2-370.6)						
Larynx						Testis					
	Male	3	3.4	nc	(nc-nc)						
	Female	1	0.9	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	11	5.6	197.9	(98.6-354.1)						
	Female	6	5.1	116.9	(42.7-254.4)						
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	3.5	nc	(nc-nc)						
	Female	0	1.4	nc	(nc-nc)						
Lung and Bronchus						All Sites / Types					
	Male	33	35.1	94.1	(64.7-132.1)						
	Female	45	33.8	133.3	(97.2-178.4)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

217  
Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	96	96.1	99.9	(80.9-122.0)	Male	53	48.0	110.4	(82.7-144.4)
Female	29	36.9	78.7	(52.7-113.0)	Female	77	40.5	189.9	(149.9-237.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	19	17.8	106.9	(64.3-167.0)	Male	19	13.3	142.5	(85.8-222.6)
Female	11	16.0	68.6	(34.2-122.7)	Female	9	11.5	78.5	(35.8-149.0)
Breast					Non-Hodgkin Lymphoma				
Male	4	2.8	nc	(nc-nc)	Male	64	47.6	134.5	(103.5-171.7)
Female	478	381.7	125.2	(114.2-137.0)	Female	57	45.6	125.1	(94.7-162.1)
Cervix Uteri					Oral Cavity & Pharynx				
Female	9	17.6	51.2	(23.4-97.3)	Male	26	35.8	72.6	(47.4-106.4)
Colon / Rectum					Female	23	18.6	124.0	(78.6-186.0)
Male	137	147.8	92.7	(77.8-109.6)	Ovary				
Female	121	151.6	79.8	(66.2-95.4)	Female	57	39.2	145.4	(110.1-188.4)
Esophagus					Pancreas				
Male	9	23.0	39.2	(17.9-74.4)	Male	29	27.5	105.5	(70.7-151.5)
Female	9	7.4	120.8	(55.1-229.4)	Female	33	31.4	105.0	(72.3-147.4)
Hodgkin Lymphoma					Prostate				
Male	6	7.7	77.7	(28.4-169.1)	Male	426	382.5	111.4	(101.0-122.5)
Female	9	7.2	125.0	(57.0-237.3)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	42	37.4	112.4	(81.0-151.9)	Testis	Male	25	25.3	98.7	(63.8-145.6)
	Female	27	25.9	104.2	(68.6-151.6)		Female	7	16.2	43.2	(17.3-88.9)
Leukemia	Male	10	16.9	59.1	(28.3-108.6)	Thyroid	Male	17	13.0	130.6	(76.0-209.1)
	Female	2	4.6	nc	(nc-nc)		Female	42	30.5	137.7	(99.3-186.2)
Liver and Intrahepatic Bile Ducts	Male	17	17.5	97.4	(56.7-156.0)	Uteri Corpus and Uterus, NOS	Male	14	8.8	158.5	(86.6-266.0)
	Female	5	7.2	69.9	(22.5-163.2)		Female	64	74.9	85.5	(65.8-109.2)
Lung and Bronchus	Male	128	185.6	69.0	(57.5-82.0)	All Sites / Types	Male	1254	1267.1	99.0	(93.6-104.6)
	Female	118	167.0	70.7	(58.5-84.6)		Female	1303	1249.2	104.3	(98.7-110.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

218  
Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	8	7.6	104.8	(45.1-206.6)	Male	12	5.4	222.3	(114.7-388.3)
Female	4	1.9	nc	(nc-nc)	Female	8	3.1	261.2	(112.5-514.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)		Male	3	5.0	nc	(nc-nc)
Female	30	28.0	107.1	(72.2-152.8)		Female	1	2.7	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
Female	1	1.5	nc	(nc-nc)		Male	2	4.2	nc	(nc-nc)
						Female	2	1.2	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	11	12.5	88.2	(44.0-157.9)						
Female	3	7.4	nc	(nc-nc)		Female	0	2.7	nc	(nc-nc)
Esophagus						Pancreas				
Male	3	2.2	nc	(nc-nc)		Male	3	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)		Female	3	1.5	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	1.2	nc	(nc-nc)		Male	50	35.0	142.8	(106.0-188.3)
Female	1	0.5	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	3	4.0	nc	(nc-nc)		Male	4	2.1	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)
Larynx						Testis				
Male	1	1.7	nc	(nc-nc)		Male	3	2.3	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)						
Leukemia						Thyroid				
Male	0	2.9	nc	(nc-nc)		Male	0	1.3	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)		Female	2	2.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	1.9	nc	(nc-nc)						
Female	0	0.4	nc	(nc-nc)		Female	6	5.3	113.6	(41.5-247.3)
Lung and Bronchus						All Sites / Types				
Male	10	15.8	63.2	(30.3-116.3)		Male	118	118.9	99.2	(82.1-118.8)

Female 7 9.4 74.5 (29.8-153.5)

Female 79 79.7 99.1 (78.4-123.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

219

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	11	17.4	63.2	(31.5-113.0)	Male	4	8.4	nc	(nc-nc)
Female	6	7.7	77.5	(28.3-168.6)	Female	3	7.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	3.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)	Male	10	8.4	118.5	(56.7-217.9)
Female	58	70.7	82.0	(62.3-106.0)	Female	10	9.3	107.8	(51.6-198.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	3.0	nc	(nc-nc)	Male	8	6.1	130.8	(56.3-257.8)
Colon / Rectum					Female	0	3.6	nc	(nc-nc)
Male	25	26.6	94.0	(60.8-138.8)	Ovary				
Female	39	32.3	120.7	(85.8-165.0)	Female	9	7.4	121.2	(55.3-230.1)
Esophagus					Pancreas				
Male	5	4.1	123.2	(39.7-287.5)	Male	7	4.9	142.4	(57.0-293.4)
Female	1	1.6	nc	(nc-nc)	Female	3	6.7	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				

Male	1	1.4	nc	(nc-nc)	Male	73	68.4	106.7	(83.6-134.1)
Female	0	1.3	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	8	6.6	122.1	(52.6-240.6)	Male	2	4.5	nc	(nc-nc)
Female	5	5.2	96.5	(31.1-225.2)	Female	3	3.5	nc	(nc-nc)
Larynx					Testis				
Male	2	3.0	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)					
Leukemia					Thyroid				
Male	9	5.2	173.7	(79.2-329.7)	Male	0	1.5	nc	(nc-nc)
Female	3	5.2	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	3.0	nc	(nc-nc)					
Female	2	1.5	nc	(nc-nc)	Female	18	14.0	128.8	(76.3-203.6)
Lung and Bronchus					All Sites / Types				
Male	46	33.6	136.7	(100.1-182.4)	Male	234	226.5	103.3	(90.5-117.4)
Female	32	34.5	92.6	(63.4-130.8)	Female	232	245.4	94.5	(82.8-107.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

220

#### North Andover

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	30	25.5	117.5	(79.3-167.8)	Male	20	13.6	146.8	(89.6-226.8)
Female	12	10.5	114.6	(59.2-200.3)	Female	15	11.7	128.3	(71.7-211.6)

Brain and Other Nervous System						Multiple Myeloma				
Male	5	5.3	94.3	(30.4-220.0)		Male	5	3.6	138.0	(44.5-322.0)
Female	7	4.7	148.2	(59.4-305.4)		Female	5	3.3	153.3	(49.4-357.7)
Breast						Non-Hodgkin Lymphoma				
Male	2	0.8	nc	(nc-nc)		Male	17	13.4	127.2	(74.1-203.7)
Female	103	109.7	93.9	(76.6-113.8)		Female	7	13.1	53.6	(21.5-110.4)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	9	10.4	86.9	(39.7-165.0)
Female	4	5.2	nc	(nc-nc)		Female	4	5.3	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	31	39.7	78.1	(53.0-110.8)						
Female	54	43.5	124.2	(93.3-162.0)		Female	14	11.3	124.4	(67.9-208.7)
Esophagus						Pancreas				
Male	9	6.3	142.2	(64.9-270.0)		Male	9	7.4	120.9	(55.2-229.6)
Female	4	2.1	nc	(nc-nc)		Female	4	9.0	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	3	2.3	nc	(nc-nc)		Male	108	104.3	103.5	(84.9-125.0)
Female	1	2.1	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	11	10.6	104.2	(51.9-186.4)		Male	10	6.8	146.3	(70.0-269.1)
Female	5	7.4	67.6	(21.8-157.8)		Female	3	4.7	nc	(nc-nc)
Larynx						Testis				
Male	5	4.7	105.8	(34.1-246.8)		Male	3	4.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)						
Leukemia						Thyroid				
Male	8	8.2	97.4	(41.9-192.0)		Male	3	2.7	nc	(nc-nc)
Female	7	7.5	93.5	(37.5-192.7)		Female	9	9.0	100.4	(45.8-190.5)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	3	4.9	nc	(nc-nc)						

Female	0	2.0	nc	(nc-nc)	Female	22	21.2	103.8	(65.1-157.2)
Lung and Bronchus					All Sites / Types				
Male	51	49.8	102.5	(76.3-134.8)	Male	371	347.4	106.8	(96.2-118.2)
Female	37	47.0	78.7	(55.4-108.5)	Female	337	358.0	94.1	(84.3-104.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

221

# North Attleborough

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	22	22.2	99.2	(62.1-150.2)	Male	18	12.7	142.3	(84.3-224.9)
Female	3	8.1	nc	(nc-nc)	Female	9	10.7	83.7	(38.2-159.0)
Brain and Other Nervous System					Multiple Myeloma				
Male	7	5.1	138.4	(55.4-285.1)	Male	2	3.2	nc	(nc-nc)
Female	5	4.2	118.4	(38.2-276.3)	Female	6	2.5	236.8	(86.5-515.4)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.7	nc	(nc-nc)	Male	7	12.2	57.2	(22.9-117.8)
Female	106	96.0	110.4	(90.4-133.5)	Female	8	10.7	74.7	(32.2-147.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	5.0	nc	(nc-nc)	Male	8	9.5	84.0	(36.2-165.5)
Colon / Rectum					Female	9	4.5	201.7	(92.0-382.9)
Male	39	34.8	112.1	(79.7-153.2)	Ovary				
Female	26	32.7	79.5	(51.9-116.5)	Female	11	9.7	113.7	(56.7-203.5)
Esophagus					Pancreas				



Male	6	5.6	106.3	(38.8-231.3)	Male	9	6.5	137.8	(62.9-261.6)
Female	1	1.6	nc	(nc-nc)	Female	4	6.7	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	4	2.4	nc	(nc-nc)	Male	78	93.3	83.6	(66.1-104.4)
Female	3	2.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	10	9.6	103.7	(49.6-190.7)	Male	4	5.9	nc	(nc-nc)
Female	1	6.2	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
Larynx					Testis				
Male	3	4.3	nc	(nc-nc)	Male	6	4.5	133.0	(48.6-289.4)
Female	1	1.1	nc	(nc-nc)					
Leukemia					Thyroid				
Male	4	7.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	10	6.1	162.8	(77.9-299.4)	Female	12	9.1	132.3	(68.3-231.1)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	4.5	nc	(nc-nc)					
Female	0	1.6	nc	(nc-nc)	Female	17	18.4	92.2	(53.7-147.7)
Lung and Bronchus					All Sites / Types				
Male	54	44.0	122.6	(92.1-160.0)	Male	306	311.7	98.2	(87.5-109.8)
Female	42	38.1	110.3	(79.5-149.0)	Female	305	299.4	101.9	(90.8-114.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	8	4.9	161.8	(69.7-318.8)		Male	2	2.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)		Female	1	2.0	nc	(nc-nc)
Brain and Other Nervous System						Multiple Myeloma				
Male	3	1.0	nc	(nc-nc)		Male	2	0.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)		Male	3	2.5	nc	(nc-nc)
Female	19	19.0	99.9	(60.1-156.0)		Female	0	2.3	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	0	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)		Female	0	0.9	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	4	7.6	nc	(nc-nc)						
Female	6	7.2	82.9	(30.3-180.5)		Female	1	1.9	nc	(nc-nc)
Esophagus						Pancreas				
Male	0	1.2	nc	(nc-nc)		Male	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)		Female	1	1.5	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.4	nc	(nc-nc)		Male	15	19.5	76.9	(43.0-126.8)
Female	1	0.4	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	2	2.0	nc	(nc-nc)		Male	1	1.3	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)
Larynx						Testis				
Male	0	0.9	nc	(nc-nc)		Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)						
Leukemia						Thyroid				
Male	0	1.6	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)

Female	0	1.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	0.9	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	6	3.7	161.8	(59.1-352.2)
Lung and Bronchus					All Sites / Types				
Male	8	9.6	83.6	(36.0-164.7)	Male	55	65.8	83.6	(63.0-108.8)
Female	6	8.4	71.8	(26.2-156.3)	Female	50	61.6	81.2	(60.3-107.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

223

#### North Reading

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	12.6	71.6	(32.7-136.0)	Male	12	7.0	170.8	(88.2-298.4)
Female	0	4.4	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	2.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	2	6.8	nc	(nc-nc)
Female	56	52.4	107.0	(80.8-138.9)	Female	8	5.7	140.7	(60.6-277.3)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	2.6	nc	(nc-nc)	Male	5	5.5	90.9	(29.3-212.2)
Colon / Rectum					Female	4	2.4	nc	(nc-nc)
					Ovary				

	Male	15	19.8	75.9	(42.5-125.2)
	Female	18	17.3	104.3	(61.8-164.9)
Esophagus					
	Male	3	3.3	nc	(nc-nc)
	Female	1	0.9	nc	(nc-nc)
Hodgkin Lymphoma					
	Male	0	1.2	nc	(nc-nc)
	Female	1	1.0	nc	(nc-nc)
Kidney & Renal Pelvis					
	Male	5	5.6	89.8	(28.9-209.6)
	Female	5	3.4	148.2	(47.7-345.8)
Larynx					
	Male	1	2.5	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)
Leukemia					
	Male	1	4.1	nc	(nc-nc)
	Female	3	3.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					
	Male	2	2.6	nc	(nc-nc)
	Female	0	0.8	nc	(nc-nc)
Lung and Bronchus					
	Male	23	25.7	89.5	(56.7-134.3)
	Female	21	21.1	99.7	(61.7-152.4)

	Female	5	5.2	96.0	(30.9-223.9)
Pancreas					
	Male	5	3.7	134.5	(43.4-314.0)
	Female	4	3.6	nc	(nc-nc)
Prostate					
	Male	43	56.2	76.6	(55.4-103.2)
Stomach					
	Male	1	3.3	nc	(nc-nc)
	Female	0	1.8	nc	(nc-nc)
Testis					
	Male	5	2.1	240.8	(77.6-561.9)
Thyroid					
	Male	1	1.4	nc	(nc-nc)
	Female	4	4.5	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					
	Female	6	10.3	58.4	(21.3-127.1)
All Sites / Types					
	Male	141	179.5	78.6	(66.1-92.7)
	Female	155	161.0	96.3	(81.7-112.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Northampton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	23	29.3	78.6	(49.8-117.9)	Male	16	15.1	105.6	(60.3-171.6)
Female	17	12.0	142.2	(82.8-227.7)	Female	11	13.5	81.4	(40.6-145.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	5.5	90.1	(29.1-210.4)	Male	9	4.1	219.1	(100.0-416.0)
Female	2	5.3	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.9	nc	(nc-nc)	Male	11	14.8	74.1	(36.9-132.6)
Female	131	121.5	107.8	(90.1-127.9)	Female	12	15.0	80.1	(41.3-139.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	7	5.8	119.7	(47.9-246.6)	Male	15	11.2	134.0	(74.9-221.0)
Colon / Rectum					Female	10	6.0	167.9	(80.4-308.8)
Male	46	45.2	101.8	(74.5-135.8)	Ovary				
Female	44	50.3	87.4	(63.5-117.4)	Female	18	12.7	142.2	(84.2-224.7)
Esophagus					Pancreas				
Male	10	7.0	142.2	(68.1-261.6)	Male	7	8.4	83.3	(33.4-171.6)
Female	3	2.5	nc	(nc-nc)	Female	3	10.4	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	2	2.5	nc	(nc-nc)	Male	92	115.1	79.9	(64.4-98.0)
Female	3	2.8	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	6	7.8	77.1	(28.1-167.7)
Male	11	11.6	94.8	(47.3-169.6)	Female	5	5.5	91.3	(29.4-213.0)
Female	19	8.3	229.2	(137.9-357.9)	Testis				
Larynx					Male	7	4.5	156.7	(62.8-322.9)
Male	8	5.2	154.1	(66.3-303.6)					

Female	1	1.4	nc	(nc-nc)
Leukemia				
Male	9	8.9	100.9	(46.0-191.5)
Female	6	8.5	70.7	(25.8-154.0)
Liver and Intrahepatic Bile Ducts				
Male	3	5.5	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)
Lung and Bronchus				
Male	63	56.6	111.4	(85.6-142.5)
Female	68	52.7	129.0	(100.1-163.5)

#### Thyroid

Male	2	2.9	nc	(nc-nc)
Female	10	10.6	93.9	(45.0-172.7)
Uteri Corpus and Uterus, NOS				
Female	18	23.2	77.7	(46.1-122.9)
All Sites / Types				
Male	375	388.0	96.6	(87.1-106.9)
Female	410	404.8	101.3	(91.7-111.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

225

#### Northborough

##### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	11.9	50.6	(18.5-110.2)	Male	4	6.9	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	2.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	6	6.6	91.2	(33.3-198.4)
Female	44	51.9	84.7	(61.5-113.7)	Female	2	5.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				

Colon / Rectum	Female	3	2.6	nc	(nc-nc)	Male	7	5.4	130.4	(52.3-268.7)
						Female	8	2.4	338.8	(145.9-667.7)
	Male	12	18.7	64.0	(33.0-111.8)	Ovary				
Esophagus	Female	15	16.3	91.8	(51.4-151.5)	Female	4	5.1	nc	(nc-nc)
						Pancreas				
	Male	0	3.1	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Hodgkin Lymphoma	Female	2	0.8	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
						Prostate				
	Male	0	1.2	nc	(nc-nc)	Male	62	52.7	117.6	(90.2-150.8)
Kidney & Renal Pelvis	Female	0	1.0	nc	(nc-nc)					
						Stomach				
	Male	6	5.4	111.6	(40.8-242.9)	Male	0	3.1	nc	(nc-nc)
Larynx	Female	2	3.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
						Testis				
	Male	0	2.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Leukemia	Female	0	0.6	nc	(nc-nc)					
						Thyroid				
	Male	2	4.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	2	3.1	nc	(nc-nc)	Female	7	4.6	150.7	(60.4-310.6)
						Uteri Corpus and Uterus, NOS				
	Male	1	2.5	nc	(nc-nc)					
Lung and Bronchus	Female	1	0.8	nc	(nc-nc)	Female	7	10.1	69.5	(27.9-143.3)
						All Sites / Types				
	Male	16	24.2	66.0	(37.7-107.2)	Male	142	170.8	83.1	(70.0-98.0)
	Female	19	20.0	94.8	(57.1-148.1)	Female	133	156.9	84.7	(71.0-100.4)

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

226

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	12	13.3	90.4	(46.6-157.9)	Male	10	6.8	147.0	(70.4-270.3)
Female	3	5.5	nc	(nc-nc)	Female	7	5.8	119.8	(48.0-246.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	2.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.4	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
Female	47	54.0	87.0	(63.9-115.7)	Female	11	6.7	163.6	(81.5-292.7)
Cervix Uteri					Oral Cavity & Pharynx				
Female	6	2.6	234.3	(85.6-510.0)	Male	6	5.0	119.8	(43.8-260.9)
Colon / Rectum					Female	1	2.7	nc	(nc-nc)
Male	15	20.4	73.4	(41.0-121.1)	Ovary				
Female	30	22.9	130.8	(88.2-186.8)	Female	2	5.6	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	3.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	1.2	nc	(nc-nc)	Male	50	51.7	96.7	(71.8-127.5)
Female	0	1.0	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	5	3.5	141.8	(45.7-330.8)
Male	7	5.2	134.1	(53.7-276.4)					



Larynx	Female	5	3.7	133.7	(43.1-312.0)	Testis	Female	0	2.5	nc	(nc-nc)
	Male	1	2.3	nc	(nc-nc)		Male	2	2.1	nc	(nc-nc)
Leukemia	Female	2	0.6	nc	(nc-nc)	Thyroid					
	Male	4	4.2	nc	(nc-nc)		Male	4	1.3	nc	(nc-nc)
	Female	1	3.9	nc	(nc-nc)		Female	4	4.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	4	2.4	nc	(nc-nc)						
	Female	0	1.1	nc	(nc-nc)		Female	12	10.4	115.8	(59.8-202.3)
Lung and Bronchus						All Sites / Types					
	Male	21	25.4	82.6	(51.1-126.3)		Male	160	175.3	91.3	(77.7-106.6)
	Female	20	24.0	83.5	(51.0-128.9)		Female	171	181.4	94.3	(80.7-109.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

227

#### Northfield

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	3.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Cervix Uteri	Male	0	0.1	nc	(nc-nc)
	Female	13	13.0	99.7	(53.0-170.6)
Colon / Rectum	Female	0	0.6	nc	(nc-nc)
	Male	3	5.0	nc	(nc-nc)
Esophagus	Female	5	4.9	101.1	(32.6-235.8)
	Male	1	0.8	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.2	nc	(nc-nc)
	Male	1	0.3	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.2	nc	(nc-nc)
	Male	0	1.3	nc	(nc-nc)
Larynx	Female	3	0.9	nc	(nc-nc)
	Male	0	0.6	nc	(nc-nc)
Leukemia	Female	0	0.2	nc	(nc-nc)
	Male	1	1.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	0	0.8	nc	(nc-nc)
	Male	0	0.6	nc	(nc-nc)
Lung and Bronchus	Female	0	0.2	nc	(nc-nc)
	Male	4	6.3	nc	(nc-nc)
	Female	3	5.5	nc	(nc-nc)

Oral Cavity & Pharynx	Male	1	1.6	nc	(nc-nc)
	Female	5	1.5	331.0	(106.7-772.4)
Ovary	Male	1	1.3	nc	(nc-nc)
	Female	1	0.6	nc	(nc-nc)
Pancreas	Female	2	1.3	nc	(nc-nc)
	Male	1	0.9	nc	(nc-nc)
Prostate	Female	1	1.0	nc	(nc-nc)
	Male	8	13.3	60.3	(26.0-118.8)
Stomach	Male	1	0.8	nc	(nc-nc)
	Female	2	0.5	nc	(nc-nc)
Testis	Male	0	0.4	nc	(nc-nc)
	Female	2	1.0	nc	(nc-nc)
Thyroid	Male	1	0.3	nc	(nc-nc)
	Female	2	1.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	2	2.5	nc	(nc-nc)
	Male	29	43.5	66.7	(44.6-95.7)
All Sites / Types	Female	43	41.7	103.1	(74.6-138.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

228  
Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	12	12.1	99.6	(51.4-173.9)	Male	5	7.2	69.1	(22.3-161.3)
Female	6	4.6	130.8	(47.7-284.6)	Female	13	6.4	201.9	(107.4-345.2)
Brain and Other Nervous System					Multiple Myeloma				
Male	7	3.0	232.2	(93.0-478.4)	Male	1	1.8	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	3	7.0	nc	(nc-nc)
Female	43	56.1	76.7	(55.5-103.3)	Female	7	6.2	113.2	(45.4-233.3)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	3.0	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Colon / Rectum					Female	3	2.6	nc	(nc-nc)
Male	21	19.1	109.9	(68.0-168.0)	Ovary				
Female	15	18.5	81.2	(45.4-134.0)	Female	4	5.7	nc	(nc-nc)
Esophagus					Pancreas				
Male	4	3.2	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	6	3.8	159.3	(58.2-346.8)
Hodgkin Lymphoma					Prostate				
Male	0	1.5	nc	(nc-nc)	Male	48	52.7	91.2	(67.2-120.9)
Female	1	1.4	nc	(nc-nc)					

Kidney & Renal Pelvis						Stomach				
Male	7	5.5	126.5	(50.7-260.6)		Male	5	3.3	153.0	(49.3-357.1)
Female	3	3.6	nc	(nc-nc)		Female	3	2.0	nc	(nc-nc)
Larynx						Testis				
Male	4	2.4	nc	(nc-nc)		Male	3	2.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)						
Leukemia						Thyroid				
Male	3	4.3	nc	(nc-nc)		Male	1	1.6	nc	(nc-nc)
Female	1	3.7	nc	(nc-nc)		Female	8	5.6	141.9	(61.1-279.6)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	3	2.6	nc	(nc-nc)						
Female	2	0.9	nc	(nc-nc)		Female	12	10.8	111.3	(57.5-194.5)
Lung and Bronchus						All Sites / Types				
Male	28	24.3	115.5	(76.7-166.9)		Male	172	175.1	98.2	(84.1-114.1)
Female	24	21.5	111.8	(71.6-166.3)		Female	170	173.8	97.8	(83.7-113.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

229

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	10.5	66.7	(26.7-137.4)	Male	9	5.6	159.5	(72.8-302.9)
Female	3	3.7	nc	(nc-nc)	Female	8	4.4	183.5	(79.0-361.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)

Breast	Female	1	1.7	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Cervix Uteri	Female	52	42.7	121.8	(91.0-159.7)
	Male	17	16.5	103.3	(60.1-165.4)
Colon / Rectum	Female	1	1.9	nc	(nc-nc)
	Male	15	14.8	101.5	(56.7-167.4)
Esophagus	Female	3	2.7	nc	(nc-nc)
	Male	0	0.7	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	0.9	nc	(nc-nc)
	Male	0	0.7	nc	(nc-nc)
Kidney & Renal Pelvis	Female	4	4.5	nc	(nc-nc)
	Male	4	2.7	nc	(nc-nc)
Larynx	Female	1	2.1	nc	(nc-nc)
	Male	0	0.5	nc	(nc-nc)
Leukemia	Female	2	3.3	nc	(nc-nc)
	Male	3	2.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	2	2.1	nc	(nc-nc)
	Male	1	0.7	nc	(nc-nc)
Lung and Bronchus					

Non-Hodgkin Lymphoma	Female	2	1.1	nc	(nc-nc)
	Male	6	5.5	109.4	(40.0-238.2)
Oral Cavity & Pharynx	Female	2	4.6	nc	(nc-nc)
	Male	3	4.5	nc	(nc-nc)
Ovary	Female	2	2.0	nc	(nc-nc)
	Male	2	4.3	nc	(nc-nc)
Pancreas	Female	3	3.1	nc	(nc-nc)
	Male	3	3.0	nc	(nc-nc)
Prostate	Female	41	46.1	88.9	(63.8-120.7)
	Male	3	2.8	nc	(nc-nc)
Stomach	Female	0	1.6	nc	(nc-nc)
	Male	0	1.4	nc	(nc-nc)
Testis	Female	5	3.3	150.3	(48.4-350.7)
	Male	2	1.1	nc	(nc-nc)
Thyroid	Female	9	8.5	105.9	(48.3-201.0)
	Male				
Uteri Corpus and Uterus, NOS	Female				
	Male				
All Sites / Types	Female				
	Male				

Male	13	21.1	61.6	(32.8-105.4)
Female	10	17.2	58.1	(27.8-106.8)

Male	126	147.0	85.7	(71.4-102.1)
Female	129	132.1	97.6	(81.5-116.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

230  
Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	26	33.9	76.6	(50.0-112.3)	Male	27	16.6	162.8	(107.2-236.9)
Female	10	14.0	71.4	(34.2-131.4)	Female	20	14.1	141.5	(86.4-218.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	9	6.1	146.9	(67.1-279.0)	Male	7	4.7	150.3	(60.2-309.6)
Female	10	5.7	175.8	(84.2-323.4)	Female	5	4.4	114.6	(36.9-267.4)
Breast					Non-Hodgkin Lymphoma				
Male	0	1.0	nc	(nc-nc)	Male	12	16.5	72.7	(37.5-127.0)
Female	114	133.3	85.5	(70.5-102.7)	Female	14	16.9	82.7	(45.2-138.7)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	6.0	nc	(nc-nc)	Male	7	12.0	58.3	(23.3-120.1)
Colon / Rectum					Female	4	6.7	nc	(nc-nc)
Male	53	51.9	102.1	(76.5-133.6)	Ovary				
Female	65	57.9	112.3	(86.6-143.1)	Female	14	13.9	101.0	(55.2-169.5)
Esophagus					Pancreas				
Male	11	7.9	138.4	(69.0-247.7)	Male	8	9.6	83.6	(36.0-164.7)
Female	6	2.8	212.6	(77.6-462.8)	Female	12	12.1	99.1	(51.1-173.1)

Hodgkin Lymphoma					Prostate				
Male	1	2.7	nc	(nc-nc)	Male	157	133.8	117.3	(99.7-137.2)
Female	0	2.4	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	12	12.9	93.2	(48.1-162.7)	Male	14	8.8	158.3	(86.5-265.7)
Female	13	9.5	136.6	(72.7-233.6)	Female	5	6.2	80.1	(25.8-187.0)
Larynx					Testis				
Male	7	5.8	120.1	(48.1-247.5)	Male	3	4.8	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)					
Leukemia					Thyroid				
Male	13	10.1	128.6	(68.4-219.9)	Male	6	3.1	195.9	(71.5-426.3)
Female	12	9.4	127.6	(65.8-222.9)	Female	13	10.2	127.9	(68.0-218.7)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	7	6.0	117.0	(46.9-241.1)					
Female	2	2.7	nc	(nc-nc)	Female	28	26.3	106.6	(70.9-154.1)
Lung and Bronchus					All Sites / Types				
Male	73	65.8	111.0	(87.0-139.6)	Male	475	443.3	107.2	(97.7-117.2)
Female	70	62.8	111.5	(86.9-140.8)	Female	469	453.6	103.4	(94.3-113.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;